



Arthur Michael Feldman, M.D., Ph.D.

Candidate for
Dean, School of Medicine

UMDNJ – New Jersey Medical School

CONFIDENTIAL REPORT

This report has been prepared for the exclusive use of **UMDNJ – New Jersey Medical School** in conjunction with a search for **Dean, School of Medicine**. It is recommended that circulation be limited to designated executives concerned with the candidate selection process. The information contained herein has been voluntarily provided by **Arthur Michael Feldman, M.D., Ph.D.** and is subject to verification by Korn/Ferry International.



CURRICULUM VITAE

Arthur Michael Feldman, M.D., Ph.D.

Office Address: Jefferson Medical College, Department of Medicine
1025 Walnut Street, College Building, Suite 822
Philadelphia, PA 19107
Tel: (215) 955-6946 / Fax: (215) 955-2318
E-mail: arthur.feldman@jefferson.edu

Marital Status: Married, Susan B. Feldman, Esq.

Children: Emily Kate, 7/2/87
Elizabeth Willa, 5/14/89

Education:

1963-1966	Diploma - Baltimore City College
1966-1970	B.A. - Gettysburg College, Gettysburg, PA
1970-1973	M.S. - University of Maryland, College Park MD
1974	Ph.D. - University of Maryland, College Park, MD
1977-1981	M.D. - Louisiana State University School of Medicine, Shreveport, LA

Postgraduate Training and Fellowship Appointments:

1970-1974	Graduate Teaching Assistant, Department of Zoology, University of Maryland, College Park, MD
1974-1977	Postdoctoral Fellow, Department of Pediatrics/Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD
1981-1982	Intern, Dept. of Medicine, The Johns Hopkins Hospital, Baltimore, MD
1982-1984	Assistant Resident, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD
1983-1986	Clinical Fellow, Division of Cardiology, The Johns Hopkins Hospital, Baltimore, MD
1994	Design for Effective Management in Health Care Program, The Wharton School, Philadelphia, PA

Academic Appointments:

1977-1981	Clinical Instructor, Dept. of Otolaryngology, LSU School of Medicine in Shreveport, Shreveport, LA
1986-1991	Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
1990-1994	Joint Appointment in Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD
1990-1994	Director, Heart Failure Research Program, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD
1991-1994	Associate Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
1991-1994	Director, The Belfer Laboratory for Molecular Biology of Heart Failure, The Johns Hopkins University School of Medicine



1994-1998 Director, University of Pittsburgh Heart Institute, University of Pittsburgh Medical Center, Pittsburgh, PA
1994-2002 Harry S. Tack Professor of Medicine, The University of Pittsburgh School of Medicine, Pittsburgh, PA
1994-2002 Chief, Division of Cardiology, University of Pittsburgh School of Medicine. Pittsburgh, PA
1996-2002 Professor of Cell Biology and Physiology
1998-2002 Member, Graduate Faculty, Department of Human Genetics, University of Pittsburgh
1999-2002 Director, The Cardiovascular Institute of the UPMC Health System
2002- Magee Professor and Chairman, Department of Medicine, Jefferson Medical College

Hospital and Administrative Appointments:

1986-1994 Attending Physician, Cardiology Consult Service, Johns Hopkins Hospital
1986-1994 Attending Physician, Cardiology Consult Service, Johns Hopkins
1986-1994 Attending Physician, Cardiomyopathy Service, Johns Hopkins Hospital
1986-1994 Attending Physician, Heart and Heart-Lung Transplant Service, Johns Hopkins Hospital
1986-1994 Attending Physician, Clinical Skills Course
1991-1994 Attending Physician, Nelson-Baker Medical Service
1988-1994 Board of Medical Student Advisors
1990-1994 Teaching Faculty, Medical Physiology (Cardiovascular Section)
1991-1994 Teaching Faculty, Pharmacology and Therapeutics (CV Section)
1990-1994 Research Preceptor, Four Schools Physician Scientist Training Program
1991-1994 Member, Pharmacy and Therapeutics Committee
1994-2002 Attending Physician, University of Pittsburgh Medical Center
1994-2002 Member, Total Quality Council, University of Pittsburgh Medical Center
1994-1998 Member, Managed Care Committee
1995-2000 President, UPMC Cardiology Network (Heart Groups 1-10)
1996-2002 Member, Clinical Trials Steering Committee
1997-2002 Member, Quality Improvement Committee, Cardiology Subcommittee Tri-State Health System
1997-1999 UPMC Presbyterian/Shadyside Physician Leadership Forum
1998-2002 Member, Executive Steering Committee
1998-2002 Member, Chairmen/Management Group
1998-2002 Board Member, University of Pittsburgh Physicians
1999-Pres Member, UPP Clinical Operations Committee
2001-2002 Course Director, Cardiology Grand Rounds
2001-2002 Member, CVI Quality Assurance Committee
2001-2002 Member, UPMC-Presbyterian Technology Advisory Committee
2002- Executive Council, JMC
2002- Committee on Faculty Affairs, JMC
2002- Executive Council, JUP
2002- Board of Directors, JUP
2002- Clinical Care Committee, JUP
2002- Executive Committee of the Medical Staff, TJUH
2002- Executive Oversight Committee, Project Care, TJUH
2002-2004 Presidential Search Committee, TJU



2003	Advisory Board, Office of Health Policy, TJU
2003-2005	Appointments and Promotions Committee, JMC
2004-2006	EHR Steering Committee, Chairman, TJUH
2004-2005	Search Committee, Chair of Department of Surgery
2004-2006	Search Committee, Director Kimmel Cancer Center
2004-	Joint Clinical Management Committee, TJU
2004-	Committee on Committees, JMC
2006-	JUP Management Committee
2006-	Ambulatory Care Building Steering Committee, TJU
2007-	Search Committee, Chair of Department of Pediatrics
2007-	Chairman, Committee on Committees, JMC

Specialty Certification:

1984	American Board of Internal Medicine
1989	Subspecialty in Cardiovascular Diseases

Licensure:

1981	State of Louisiana
1986	Board of Medical Examiners/Maryland
1994	State Board of Medicine/Pennsylvania

Awards, Memberships, Honors, and in Honorary Societies:

2007	Commencement Speaker, University of Maryland, College of Chemical and Life Sciences, May 21, 2007, College Park, MD
2007	Fellow of the American College of Physicians
2004	Interurban Clinical Club
2001	Fellow of the American Heart Association (FAHA)
2001	Association American Physicians
2000	Howard Gillman Distinguished Visiting Scientist, Cornell Medical College, Division of Cardiovascular Pathophysiology
2000	Carlyle Stout Visiting Professor, University of Utah School of Medicine
1998	Pfizer Visiting Professor, Boston University School of Medicine
1997	Rolex Achievement Award (The Lacrosse Foundation and USILA)
1995	Association of University Cardiologists
1995	Distinguished Alumnus Award, Gettysburg College
1994	Fellow, Council on Clinical Cardiology, American Heart Association
1994	American Society for Clinical Investigation
1993	Finalist, American Heart Association Boots Heart Failure Award
1992	Fellow, American College of Cardiology
1989	Established Investigator of the American Heart Association
1987	Clinician-Scientist Faculty Development Award from the Andrew W. Mellon Foundation
1981	Lewis Gottlieb Scholar Award
1981	Alpha Omega Alpha
1974	Sigma Xi
1969	Beta Beta Beta



Lay Awards:

1996	Listed among the most outstanding Cardiologists and "Best Doctors" in the U.S. by <u>Good Housekeeping</u> in March, 1996.
1996	Listed in "The Best Doctors in America: Northeast Region" (1996-1997), regional guide of "The Best Doctors in America, Woodward/White, Inc.
1997	Listed in "Who's Who in Medicine and Healthcare", publishers of Who's Who in America, First Edition.
1997	Listed in "Who's Who in the World", 15 th Edition
1997	Listed in "National Registry of Who's Who"
1997	Listed in "The Best Doctors in America" (1998-99)
1998	Listed in "Marquis Who's Who in America"
2003-2004	Listed in "National Registry of Who's Who"
2004-2005	Listed in "Who's Who in Medicine and Healthcare"
2005	Listed in "Who's Who in America", 2005, 59 th Edition
2007	Listed in "Who's Who in America", 2007, 61 st Edition
2007-2008	Listed in "Best Doctors in America"

Professional Societies:

International Society for Heart Research
The Johns Hopkins Medical and Surgical Association
Fellow, American College of Cardiology
American Heart Association, Basic Science Council
Association of Subspecialty Professors
American Heart Association, Fellow, Council on Clinical Cardiology
Association of Professors of Cardiology
Molecular Medicine Society
American Society of Gene Therapy
Council on Geriatric Cardiology
Heart Failure Society of America
Association of Governing Boards of Universities and Colleges
Association of University Cardiologists
Mid-Atlantic Pharmacology Society

Pharmaceutical Industry Activities:

1986-1995	Co-founder/Board Member, CPEC, Inc.
1996-1998	Co-founder/Board Member. Clinical Cardiovascular Research (C2R)
1996-1999	Consultant, Roche Laboratories
1988	Consultant, Merck & Co, Inc.
1996	US Heart Failure Advisory Council, SmithKline Beecham
1996-Pres	Steering Committee-International EECF Registry
1997-Pres	Cardiokine, Inc., Founder and Board Member
1997	Consultant, Immunex, Inc.
1998-Pres	Consultant, Heart Failure Advisory Board, Guidant Corporation
1998	Heart Failure Advisory Panel, Schering-Plough
1999-2002	Scientific Advisory Board, Myogen, Inc.
1999-2004	Co-Chairman, Steering Committee for COMPANION Study, Guidant
1999-2000	Toprol-XL Heart Failure Advisory Board, AstraZeneca
1999	Experts Panel Discussion, Novartis



1999	Levosimendan Advisory Board, Abbott
2000	Heart Failure/Post-MI Advisory Board, Novartis
2001	Consultant, Merrill-Lynch
2001	Consultant, MAVERICK Ventures
2001	Consultant, CV Therapeutics
2003	AstraZeneca Heart Failure Advisory Board

Editorial Positions:

1990-Pres	Editorial Board, Heart Failure
1993-2000	Editorial Board, Journal of the American College of Cardiology
1993-2006	Editorial Board, Journal of Cardiac Failure
1994-Pres	Senior Editor, Congestive Heart Failure
1994-2004	Editorial Board, Journal of Cardiovascular Pharmacology and Therapeutics
1994-2000	Editorial Board, Circulation Research
1995-Pres	Editorial Board, Heart Failure Review
1996	Guest Editor, Circulation
1998-2001	Editorial Board, Journal of Cardiovascular Pharmacology
1998-2001	Editorial Board, Clinical Cardiology
1999-	Editor, Heart Failure Society News
1994-2001	Associate Editor, Journal of Cardiac Failure
2000-2007	Editorial Board, Journal of Molecular and Cellular Cardiology
2000	Editorial Board, American Journal of Cardiovascular Drugs
2002-2004	Editorial Board, Journal of American College of Cardiology
2003-2005	Assistant Editor, Cardiosource Clinical Trials, ACCF
2003-	Editorial Board, Italian Heart Journal
2003	Guest Editor-in-Chief, Device Therapy in Clinical Cardiology
2003-2004	Guest Editor, Journal of American College of Cardiology
2003	Guest Editor, Journal of Cardiac Failure
2003-2008	Editorial Advisory Panel, Expert Review of Cardiovascular Therapy
2004-	Editorial Advisory Panel, Future Cardiology
2005-	Editorial Board, Current Drug Safety
2005-	Editorial Board, American Journal of Medicine
2006-	Guest Editor, American Journal of Cardiology
2007-	Editor-in-Chief, Clinical and Translational Science

Professional Activities and Elected National Positions:

1988	Ad Hoc Reviewer, VA Merit Review Board
1992	Ad Hoc reviewer, Alberta Heritage Foundation for Medical Research
1992	Co-Chairman, Executive Committee, Multicenter Vesnarinone Study
1993	Consultant, American Medical Association, Drug Evaluations, Division of Drugs and Toxicology
1993	Ad Hoc reviewer, Medical Research Council, UK
1993-1997	Advisory Board, International Society of Heart Failure
1993-1996	Scientific Board, The Stanley J. Sarnoff Endowment for Cardiovascular Science



1993-Pres	Scientific Advisory Board, European Society of Cardiology, Task Force on Heart Failure
1994-1996	Chairman, Morbidity-Mortality Committee, VEST Trial
1994-1995	U.S. Principal Investigator, ESPRIT (Multicenter Ibopamine) Trial
1994-1996	Consultant, American Medical Association, Division of Drugs and Toxicology
1995-1998	Expert Advisory Panel in Cardiovascular and Renal Drugs in the United States Pharmacopeial Convention, Inc. (USP)
1996-Pres	Steering Committee, National EECF Patient Registry
1997-Pres	Chair, Steering Committee, WCD Multicenter CHF Study
1997-Pres	Comitato Promotora Telethon Peer Review Panel
1998-1999	Steering Committee, Multi-center ENBREL Trial
1999-Pres	Steering Committee, Renaissance Trial
1999-Pres	Steering Committee, Enoximone Phase III Trials
1999-Pres	Steering Committee, EXTEND Trial
1999-	Chair, Steering Committee, EMOTE Trial
1999-	Steering Committee, Essential Trial
1999-2003	Chairman, Data and Safety Monitoring Board (DSMB) of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), NHLBI
2000-2004	Mortality and Morbidity Classification Committee Occluded Artery Trial (OAT), NHLBI
2000	EECP Scientific Council Executive Committee
2000-	Scientific Advisory Board, Working Group on Heart Failure of the ESC
2001-	Steering Committee, IMAC Trial
2002	Scientific Advisory Board of the International Academy of Cardiology of the 8 th Congress on Heart Failure
2002	Scientific Committee, The Inter-American Society of Heart Failure (ISHF)
2002	Lecturing Faculty, Vascular Biology Working Group Grand Rounds
1997	DSMB – OPT- CHF Trial
2003	PC-HEART Steering Committee
2003	Ad Hoc Promotion Committee member, Harvard Medical School, June 20, 2003
2003	Panel Member, Critical Pathways in the Management of Acute Heart Failure Program, New York, December 6, 2003
2003	AHA Council on Clinical Cardiology's Heart Failure and Transplantation Committee
2004	Steering Committee, Randomized, Double Blind, Multicenter Study Evaluating Effects of Eplerenone vs. Placebo on Ventricular Remodeling And Collagen Formation in Patients with Left Ventricular Systolic Dysfunction and Chronic Mild to Moderate Heart Failure
2006-	International Scientific Advisory Board, International Congress of Cardiomyopathies and Heart Failure (ICCHF)
2007	Member, Ad Hoc Promotions Committee, Harvard Medical School
2008	Member, External Advisory Board, Clinical and Translational Science Institute, University of Pittsburgh

American Board of Internal Medicine:

2002	RA Committee for Cardiovascular Disease
------	---



American College of Cardiology:

1995-2002	Abstract Reviewer, American College of Cardiology
1996-1997	Judging Committee, Young Investigators Awards Competition, American College of Cardiology
1998	Writing Group, 30 th Bethesda Conference, Future of Academic Cardiology Member, ACC/AHA Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure
1999-2001	Cardiovascular Subspecialty Societies Leadership Group
2000-2003	Member, International Committee
2000	Committee Member, Ad Hoc Task Force on Cardiovascular Relative Value Update
2000	Core Cardiology Training Symposium (COCATS), Writing Group
2001	Heart Failure GAP Advisory Panel
2002	ACC Cardio Contributor
2002- 2005	ACC Alternate Representative to the Association of Subspecialty
2003-2004	Working Group, Task Force on Workforce
2003- 2006	Member, Heart Failure and Transplant Committee
2006	Writing Group Member, Mechanical Cardio Support

American Heart Association:

1993-1996	Katz Award Prize Committee
1995-Pres	Heart Failure Committee, Basic Science Council
1996-1997	Board Member, Western Pennsylvania Affiliate
1996-Pres	Abstract Reviewer
1998-2000	Program Committee, Annual Scientific Session
1998-2001	Executive Committee, Council on Clinical Cardiology
1998-2002	Mid-Atlantic Research Peer Review Consortium Committee
1998	Team Leader, Program Committee
1999	Advisory Board, Allegheny Division of AHA
2000-2002	Co-Chair, Expert Panel on Translational Biology and Functional Genomics
2001-2002	Member, Medical Editorial Board
2001-	Fellow of the Council on Basic Cardiovascular Sciences
2001-	Fellow of the Council on Clinical Cardiology
2002-2003	Member, Functional Genomics IWG Steering Committee
2006	Writing Group Member, Endomyocardial Biopsy Guidelines

Heart Failure Society of America:

1995-1998	Secretary
1995-1998	Executive Council
1995-1998	Program Committee
1995-1998	Registry Committee
1998-2000	President
1998-2000	Chair, Ad Hoc Committee, Heart Failure Awareness Week
2000-2002	Chairman, Nominating Committee
2000-2001	Chair, Public Awareness and Public Policy Committee
2000-2002	Executive Committee



2000-2002 Education Committee
2003- Chair, Publications Committee
2003 JNC New Investigator Award Committee
2005- Chair, Lifetime Achievement Award Committee

Association of Professors of Cardiology:

1996-1997 Nominating Committee
1997-1998 Task Force on Managed Care
1998-2000 Councilor
1999-2000 Task Force, Advancement of Academic Cardiology
2000-2001 Secretary/Treasurer
2001-2002 President-Elect
2002-2003 President

Association of University Cardiologists:

2000-2002 Councilor

American Society of Gene Therapy

2002-2004 Cardiovascular Committee

Association of Professors of Medicine

2004-2006 Advocacy Advisory Board
2007- Research Committee

National Institutes of Health:

1989 Consultant, Hypertension Specialized Centers of Research (SCOR),
Research Review Committee B
1990 Consultant, Cardiovascular Study Section, Nat Heart, Lung & Blood
Institute
1992 Ad Hoc member, Training Grants Review Committee, National Heart,
Lung and Blood Institute
1992-1996 Mem. Special Emphasis Panel, National Heart, Lung and Blood Institute
1994 Ad Hoc Reviewer, Cardiovascular and Renal Study Section (B), NHLBI
1995 Ad Hoc Reviewer, Cardiovascular and Renal Study Section (B), NHLBI
1996 Cardiovascular Aging Advisory Group Panel, National Institutes
on Aging, National Institutes of Health
1996-2001 Member, Cardiovascular and Renal Study Section (B), NHLBI
1998 Ad Hoc Reviewer, Cardiovascular Study Section (A), NHLBI
1998 Member, Special Emphasis Panel "Heart Failure RFA", NHLBI
1998 NHLBI Program Project Grant Reviewer
1999-2003 Chairman, Data and Safety Monitoring Committee, ESCAPE Trial
2000- Mortality and Morbidity Classification Committee (MMCC), Occluded
Artery Trial (OAT), NHLBI
2000 Planning Operation Committee STICH Trial, NIH
2002 Co-chairman, "Form and Function: New views on development, disease
and therapies for the heart", Bethesda, MD
2006 Special Emphasis Panel (Innovative Research Grant Program)
2007 NHLBI Special Review Committee
2006 NIH, NHLBI Scientific Review Group, HLBPS Workgroup 005, February



7, 2006

Community Activities:

1992-1994 Board Member, Mt. Washington Improvement Association

1996-1998 Chairman, Task Force for Biological Sciences and Psychology, Gettysburg College

1998-2004 Board of Trustees, Gettysburg College

1998-2001 Academic Affairs Committee, Gettysburg College

2001-2002 College Relations Committee, Gettysburg College

2005- Parents' Committee (Exec Comm), Middlebury College

2005-2006 Chair, Upper School Fundraising Committee, The Baldwin School

2007- Parents' Committee, Duke University

Recent Grant Support:

“Congestive Heart Failure in TNF α Transgenic Mice”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (PI 20%)

Agency: National Institutes of Health

Type: RO1 (HL60032-01) Period: 1998 - 2002

Total funding: \$1,209,909

“Gene Transfer during LVAD Support”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (PI 25%, Clinical Project 1)

Agency: NIH/NHLBI (part of “Cardiovascular Gene Therapy Center”, PI Joseph Glorioso, Ph.D.)

Type: RFA (HL66949-01) Period: 9/30/00 - 9/29/05

Total funding: \$14,999,992

“Role of Cytokines in Extracellular Matrix Modeling”

Principal Investigator: Yun You Li, Ph.D. (Co-Investigator 5%, Non-clinical Project 1)

Agency: NIH/NHLBI (part of “Cardiovascular Gene Therapy Center”, PI Joseph Glorioso, Ph.D.)

Type: RFA (HL66949-01) Period: 9/30/00 - 9/29/05

Total funding: \$14,999,992

“An empiric risk stratification rule for heart failure”

Principal Investigator: Donald Yealy, M.D. (Investigator, 5%)

Agency: NIH/NHLBI

Type: RO1 (HS10888-02) Period: 2000 - 2002

Total funding: \$368,554

“Cardiovascular Behavioral Medicine Research Training”

Principal Investigator: Karen Matthews (Collaborator)

Agency: National Institutes of Health

Type: Training Grant (T32-HL07560-16) Period: 1998 - 2003

“Evaluation of Ischemic Heart Disease in Women (EIHDW) – Clinical Center and Central Collection Management Center (WISE)”

Principal Investigator: Steven E. Reis, M.D. (Co-PI, 10%)

Agency: National Heart Lung Blood Institute



Type: RFP (I NO1-HV-68162) Period: 1996 - 2000

“Mechanisms of cytokine-induced arrhythmias in congestive heart failure”

Principal Investigator: Barry London, M.D., Ph.D. (Co-Investigator, 5%)

Agency: NIH/NHLBI 2000 – 2005

Type: RO1 (HL66096-01) Period: 2000 - 2005

Total funding: \$200,000

“Effects of inflammatory mediators on left ventricular performance following cardiac surgery”

Principal Investigator: John Gorcsan, III, M.D. (Consultant, 5%)

Agency: American Heart Association

Type: Grant-in-aid Period: 2000 - 2003

Total Funding: \$214,470

“Health Care Finance Administration Demonstration Project: Heart Failure Home Care”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D.

Agency: Health Care Finance Administration

Type: Demonstration Project Period: 2001 - 2004

Total Funding: \$2,800,00

“WCD Device In-Patient Study Protocol”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (5%)

Agency: LifeCor

Type: Grant Period: 1997 - 1999

“A Multicenter, Double Blind, Randomized, Parallel Captopril-Controlled Study to Evaluate the Effect of Losartan on Mortality in Patients with Symptomatic Heart Failure”

Principal Investigator: Srinivas Murali, M.D (Co-PI, 5%)

Agency: Merck and Co.

Type: Grant Period: 1997 - 2001

“Evaluation of the Effects of Toborinone on the Dose Response Relationship of Dobutamine”

Principal Investigator: Srinivas Murali, M.D. (Co-PI, 5%)

Agency: Otsuka Pharmaceuticals

Type: Grant Period: 1996 - 1999

“A Multicenter Study of the Clinical Evaluation of Enhanced External Counterpulsation in the Treatment of Patients with Coronary Artery Disease”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (Co-PI, 5%)

Agency: Vasomedical, Inc.

Type: Grant Period: 1997 - 1999

“Muticenter Double-Blind, Randomized, Placebo Controlled, Phase II/III Study of the Effect of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR:Fc) on Clinical Improvement in Patients with Chronic Heart Failure”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (5%)

Agency: Immunex, Inc.

Type: Grant Period: 1999 - 2000

“Effect of TNFR:Fc on Clinical Improvement in Patients with Class IV Congestive Heart Failure”



Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (5%)
Agency: Immunex, Inc.
Type: Grant Period: 1999 - 2002

“Wearable Cardiac Defibrillator Investigation Trial (WEARIT)”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D.
Agency: LifeCor
Type: Grant Period: 1997 - Present

“Appropriate Inotropic Therapy in the Acute Exacerbation of Congestive Heart Failure – Comparative Effects of Milrinone and Dobutamine”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D. (10%)
Agency: Sanofi Pharmaceutical, Inc.
Type: Grant Period: 1998 – 2000

Active and Pending Grant Support:

“Neurohormonal/Cytokine/ Genetic Core Laboratory – STICH Trial”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D.
Agency: NIH
Type: RO1 HL69009-01 Period: 2001 - 2006
Total funding: \$333,848

“Protective Effects of Estrogen in Aged Women with Congestive Heart Failure”

Principal Investigator: Steve Reis, M.D. (Co-PI 10%)
Agency: National Institutes of Health
Type: RO1 (AG16751) Period: 2001 - 2006
Total funding: \$1,689,994

“Role of Adenosine Receptors in Heart Failure”

Principal Investigator: Arthur M. Feldman, M.D., Ph.D.
Agency: National Institutes of Health
Type: RO1 Period: 2006-2011
Total Funding: \$1,250,000

“Novel Mechanisms for Cardiac Injury and Repair”

Principal Investigator: Walter J. Koch, PhD
Agency: National Institutes of Health
Type: PPG Period: 2008-2013
Total Funding: \$12,500,000

“Heart Failure Clinical Research Network” – pending

Principal Investigator: Arthur M. Feldman, M.D., Ph.D.
Agency: National Institutes of Health
Type: RFA Period: 2006 – 2011

Invited Lectures (selected):

- | | |
|------|---|
| 1995 | Task Force on Heart Failure of the European Society of Cardiology, Amsterdam, The Netherlands |
| 1995 | Visiting Professor, Case Western University School of Medicine |
| 1995 | Visiting Professor, West Virginia University School of Medicine |



- 1995 Visiting Professor, Medical University of South Carolina College of Medicine
1995 Bloomfield-Arnold Lecture in Cardiology, Case Western Reserve University
- 1996 Visiting Professor, Hospitals of the University of Pennsylvania. Philadelphia, PA
- 1996 Cardiovascular Seminar - American Heart Association, New Orleans LA
- 1996 Japan-US Cardiology Symposium - American Heart Association, New Orleans, LA
- 1997 Management of CHF - ACC Cardiovascular Conference, Snowshoe, WV
- 1997 Focus on Cardiology, University of Pittsburgh School of Medicine, Sheraton Station Square Hotel, Pittsburgh, PA
- 1997 Survival of Academic Cardiology- Association of Professors of Cardiology, ACC 1997, Anaheim, CA
- 1997 Clinical Frontiers in Cardiology "Management of the patient with heart Failure and Concomitant Disorders, Pittsburgh, PA
- 1997 Working Group on Heart Failure -European Society of Cardiology, Cologne Germany
- 1997 Invited speaker "Cytokines in CHF" Heart Failure Society of America Annual Scientific Session, Baltimore, MD
- 1997 Invited presentation "Therapy for CHF in the Next Century" Japanese Cardiology Society Annual Meeting, Sapporo, Japan
- 1998 Pfizer Visiting Professor, Boston University School of Medicine, Division of Cardiology
- 1998 Plenary Symposium, American College of Cardiology "Medical Therapy of Advanced Heart Failure in 1998, Atlanta, GA
- 1998 The 3rd Annual Meeting of the Egyptian Society of Medicine, "Gene Therapy for Cardiovascular Disease: Can we mend a broken heart?" Cairo, Egypt
- 1998 Principles and Perspectives in Interventional Cardiology "New Technology" Mauna Kea Resort, Hawaii
- 1998 The 2nd Annual Heart Failure Society Meeting, Boca Raton, Florida
- 1998 CV Lecture Series, Schering-Plough Research Institute "The Cytokine Theory of Heart Failure", Newark, New Jersey
- 1999 ACC 99, "Will All –Receptor antagonists replace ace inhibitors in the next Millennium in the Management of Congestive Heart Failure", New Orleans, LA
- 1999 Working Group on Heart Failure – European Society of Cardiology, Gotenberg Sweden "The Role of Inotropes in the Management of CHF"
- 1999 Invited speaker "The Cytokine Hypothesis of Heart Failure: Insight from Transgenic Models", St. George's Hospital Medical School, London
- 1999 Distinguished Guest Faculty, 4th Annual Mountain Retreat "Success with Heart Failure: New Strategies for the Evaluation and Treatment of Congestive Heart Failure", Chateau Whistler, Whistler, British Columbia, Canada, August 8-10.
- 1999 3rd Annual HFSA Meeting: "Beta Blockers: The New Reality in Heart Failure" "From Clinical Trials to Clinical Practice: What we know and do not know about beta blockers and the heart", San Francisco, CA, September 22-25.
- 1999 3rd Annual HFSA Meeting: "Heart Failure Awareness", San Francisco, CA



- 1999 3rd Annual HFSA Meeting: Advances in the Treatment of End-Stage Heart Failure "Molecular Mechanisms in the Transition from Decompensated Heart Failure", San Francisco, CA, September 22-25
- 1999 AHA, Issues in Cardiac Care: Heart Failure in the New Millenium "New Frontiers in HF Research and Management", Atlanta, GA
- 1999 Co-chair, American Heart Association, "Heart Failure: Beyond Y2K, Atlanta, GA"
- 1999 Beta-Blockers in the Management of Cardiovascular Disease: Use of Beta Blockers in Congestive Heart Failure, New York, NY
- 1999 Joint AHA/ESC Symposium: Heart Failure: Beyond Y2K, webcast
- 2000 ACC, "The New Age in the Treatment of Heart Failure: From Systemic to Molecular Approaches", Anaheim, CA
- 2000 Israel Working Group on Heart Failure, "Anti-cytokine therapy for the treatment of heart failure: from the bench to the bedside", June 15, 2000
- 2000 4th Annual HFSA Meeting, "Transitioning Basic Science to Clinical Practice",
- 2000 4th Annual HFSA Meeting, "Transitioning basic science to clinical practice", Boca Raton, FL, September 10-13, 2000
- 2000 4th Annual HFSA Meeting, "Cytokine Inhibitors in Experimental Heart Failure Models", Boca Raton, FL September 10-13, 2000
- 2000 Annual HFSA Meeting, "Herceptin Associated Heart Failure in Breast Cancer: Incidence and Treatment Options" Boca Raton, FL, September 10-13, 2000
- 2000 Media Teleconference "Heart Failure: Insights into Emerging Clinical Trials", Minneapolis, MN, September 25
- 2000 Update in Internal Medicine: 2000, "The new era in the management of heart failure", Pittsburgh, PA,
- 2000 Cardiology Update Series, "From mice to men – TNF and the treatment of heart failure", Hershey, PA, October 5 & 6
- 2000 Stout Endowed Lecture, University of Utah, October 18 & 19
- 2000 University of Chicago, October 27, 2000
- 2000 University of Chicago, Cardiology Grand Rounds, October 27, 2000
- 2000 AHA 2000, Moderator w/ Dr. Bristow - Beta Blockers in HF Update on the Clinical Trials, New Orleans, LA
- 2001 Cardiology Grand Rounds, University of Virginia, February 6, 2001
- 2001 ACC 2001, The New Age in the Treatment of Heart Failure – "Impact of beta blocker on morbidity and mortality in heart failure, March 17, 2001
- 2001 ACC 2001, Inflammatory Mediators as Emerging Targets in the Treatment of Cardiovascular Disease " Cytokine antagonism in experimental models of heart failure", March 11, 2001
- 2001 Grand Rounds, UPMC McKeesport, "New Strategies for CHF", April 3, 2001, Pittsburgh, PA
- 2001 4th International Symposium on Angiotensin II Antagonism, "The cardiovascular continuum: from hypertension to heart failure", April 4, 2001, London, United Kingdom
- 2001 Disease Management: A Series of Meetings, "How to Provide the Best Care to Heart Failure Patients, April 20-22, 2001, St. Louis, Missouri
- 2001 Incontri di Cardiologia e Pneumologia, "Update of Pathophysiology and Treatment of Heart Failure: Role of Cytokines", Roma, 24-26, Maggio, 2001
- 2001 The Cardiovascular Continuum: "The Progression of Heart Disease from Hypertension to Heart Failure", Barcelona, Spain, June 2001
- 2001 Structured Discussant, Remodeling and Progression of Heart Failure



- 2001 Symposium, Minneapolis, MN, July 12-14, 2001
- 2001 5th Annual HFSA Meeting, "Case Studies in Acute Heart Failure", Washington, DC September 9, 2001
- 2001 5th Annual HFSA Meeting, Cardiac Resynchronization Therapy: "Complementary and Contemporary Mgmt", Washington, DC; September 9, 2001
- 2001 5th Annual HFSA Meeting, "Emerging Pharmacological Therapies for Chronic HF" Cytokine Antagonists, Washington, DC September 10, 2001
- 2001 Heart Failure Summit VI, "The Impact of Heart Failure on the Practice of Medicine: Can We Prevent Heart Failure", Cleveland, OH, Oct 5 & 6, 2001
- 2001 A New Era in the Treatment of PVD: Can Medicine and Intervention Complement Surgery, New York, NY, October 18, 2001
- 2001 First Annual Lillehei Heart Institute Basic Science Symposium, "Proinflammatory Cytokines and Heart Failure Lessons from the Bench and the Bedside, Minneapolis, MN, October 23, 2001
- 2001 A New Era in the Treatment of PVD: Can Medicine and Intervention Complement Surgery, Washington, DC, November 1, 2001
- 2001 AHA Scientific Sessions 2001. Heart Failure: Progress and challenges in the New Millenium "Future Directions in Heart Failure Therapy", Anaheim, CA November 11, 2001
- 2001 Plenary Session: AHA Scientific Sessions 2001: Plenary I Congestive Heart Failure: Concept to Care "Molecular Mechanisms and Targets" Anaheim, CA, November 11, 2001
- 2001 Plenary Session: AHA Scientific Sessions 2001: New Targets for Therapeutic Interventions "Markers of Myocardial Necrosis in CHF: What Cardioprotective Agents are Viable. Anaheim, CA – November 12, 2001
- 2001 Grand Rounds: "Hypertension to Heart Failure: Disease Management Across the Cardiovascular Continuum", West Penn Hospital, February 14, 2002 Pittsburgh, PA
- 2002 8th Meeting of the U.S. Chapter of the Vascular Biology Working Group, "Insights into the Role of Inflammatory Markers in the Failing Heart" March 15, 2002, Atlanta, GA
- 2002 EECP: Current Experience and Future Directions, "Mechanisms" March 16, 2002, American College of Cardiology, Atlanta, GA
- 2002 Angina Unresponsive to Conventional Therapy, "Current Management: Enhanced Extracorporeal Counterpulsion (EECP)". March 16, 2002, American College of Cardiology, Atlanta, GA
- 2002 Special Symposium prior to 2002 Heart Failure Society of America's 6th Annual Scientific Session, "Enhanced External Counterpulsion: A Novel Potential Approach to Heart Failure, September 22, 2002
- 2002 Bernard and Helen Perlman Lecture, New Frontiers in Gene Therapy for Heart Failure, New York, New York, September 28, 2002
- 2002 Choosing a Research Project/Mentor, How to Become a Cardiovascular Investigator, NIH, Bethesda, MD, October 18, 2002
- 2002 Advances in Heart Failure Management: Drugs and Devices, American Heart Association, Chicago, IL, November 16, 2002
- 2002 American Heart Association, Interstitial Remodeling After Myocardial Infarction: A Therapeutic Target, Chicago, IL, November 17, 2002
- 2002 The La Jolla-Rome-Yamaguchi Research Conference, Therapeutic Horizons in Heart Failure, "Left Ventricular Assist Devices and Chronic Heart



- Failure: Will Resting the Heart Work?" La Jolla, CA, December 7, 2002
- 2003 Distinguished Visiting Professor, Vincent White Endowed Chair Lectureship, "Bringing the Human Genome Project to the Bedside – Implications for the Therapy of Heart Failure", University of Colorado Health Sciences Center, Denver, CO, March 12, 2003
- 2003 Symposium, Gibbon and His Heart-Lung Machine 50 Years and Beyond, "The Future of the Treatment of Heart Disease, Medical Perspective, Department of Surgery, Thomas Jefferson University, Philadelphia, PA, May 2, 2003
- 2003 NASPE, Late Breaking Clinical Trials, COMPANION Trial Results, Washington, DC, May 17, 2003
- 2003 Yale Heart Failure Symposium 2003, "The future of heart failure – the genotype and the phenotype," Yale University School of Medicine, New Haven, CT, May 28, 2003
- 2003 AACC Annual Meeting, "Biochemical changes following use of left ventricular Assist devices (LVAD), Philadelphia, PA, July 24, 2003
- 2003 HFSA Scientific Meeting, "Advancing Therapies for Left Ventricular Dysfunction" - Moderator
- 2003 ESC CONGRESS, "Cardiac Resynchronization Therapy Reduces Hospitalizations and Cardiac Resynchronization Therapy With an Implantable Defibrillator Reduces Mortality in Chronic Heart Failure" (COMPANION), Vienna, Austria, August 31, 2003
- 2003 Clinical Implications of the COMPANION Trial", Vienna, Austria, September 2003
- 2003 Beta Blockers on Trial: Presenting the Evidence for Decreased Mortality and Morbidity, Philadelphia, PA, September 17, 2003
- 2003 Cardiovascular Congress, The COMPANION Trial in Perspective, Toronto, Canada, October 28, 2003 Annual CME Symposium "Updates and Controversies in Medicine Philadelphia, PA, October 9-10, 2003
- 2004 Keynote Address, COMPANION Trial: Results and Implications, New Frontiers in Heart Failure Therapy, Integrating Devices and Pharmacotherapy, New York, NY, January 10, 2004
- 2004 Vascular Biology Working Group/Medcom, "Emerging Role of Pharmacogenics in HF Treatment", ACC, New Orleans, March 5-9, 2004
- 2004 Vasomedical Satellite Symposium on EECF Therapy, ACC, New Orleans, March 5-9, 2004
- 2004 Cytokine Blockade, Symposium/661/Investigational Med Therapy for HF, ACC, New Orleans, March 5-9, 2004
- 2004 Grand Rounds, "Pharmacogenics and the Future of Heart Failure Therapy", Tufts-New England Medical Center, April 28-29, 2004
- 2004 Overview: Future Directions in Genetic Analysis of Complex Disorders" - Genetic Determinants of Heart Failure, 8th Annual Scientific Meeting, HFSA, September 14, 2004
- 2004 Disease Modification: Focus on Cardiovascular Disease, "Immune Mechanisms in Heart Failure", Mid-Atlantic Pharmacology Society, Annual Meeting, Collegeville, PA, October 15, 2004
- 2004 Heart Failure – Preserving the Balance, "Device Therapy for Patients with Heart Failure: ICDS and Bi-V Pacing", New Orleans, LA, November 8, 2004
- 2005 "Should All Heart Failure Patients Receive a BiV ICD?" Navigating the Deadly Intersection of Coronary Artery Disease and Heart Failure Roundtable Miami, FL, February 3-5, 2005



- Without
- 2005 “Cost-Effectiveness of Cardiac Resynchronization Therapy With and A Defibrillator in COMPANION Heart Failure Patients”, ACC, Orlando, FL, March 7, 2005
- 2005 “Statin Use is Associated with a Marked Improvement in Survival in an Advanced Heart Failure Population from the COMPANION Trial”, ACC, Orlando, FL, March 8, 2005
- 2005 “Prospective Evaluation of EECF in Congestive Heart Failure: The PEECH Trial”, Late-Breaking Clinical Trials: Mechanisms and new Therapeutic Approaches, ACC, Orlando, FL, March 8, 2005
- 2005 COMPANION Cost-effectiveness Analysis, ICD Cost Effectiveness Think Tank, Washington, D.C., March 21-22, 2005
- 2005 Translational Medicine, Robert Barnes Memorial Lecture, Gettysburg College, Gettysburg, PA, April 5, 2005
- 2005 Cardiac Function & Heart Failure, ACC Highlights Meeting, April 6, 2005
- 2005 9th Annual Scientific Meeting, HFSA, “Evidence Based Care: The Role of CRT, Boca Raton, FL, Sept 18, 2005
- 2005 9th Annual Scientific Meeting, HFSA, Moderator: “Fundamentals of Basic Science for Clinicians”, Boca Raton, FL, Sept 19, 2005
- 2005 Annual Scientific Meeting HFSA, “Pharmacogenics in Heart Failure: Are Individualized Approaches Appropriate or Necessary?” Boca Raton, FL, Sept 19, 2005
- 2006 Transcatheter Cardiovascular Therapeutics, TCT 2006, Essentials of Interventional Rhythm Management, Cardiac Resynchronization Therapy: Why, when and for whom? The Guidelines and Beyond, Washington, DC, October 25, 2006
- 2006 39th Annual NY Cardiovascular Symposium, ACC, “Characterization of Heart Failure and Basis for Management - Humoral and Hormonal Pathways: Helpful for the Prognosis”, New York, NY, December 8-10, 2006
- 2007 Medicine Grand Rounds, “Personalized Therapy for Cardiovascular Disease: Myth or Reality”, University of Pennsylvania School of Medicine, February 13, 2007, Philadelphia, PA
- 2007 1st International Society of Cardiomyopathy and Heart Failure, Treatment of Heart Failure: managing heart failure patients with implanted devices,” Kyoto, Japan, March 13, 2007
- 2007 71st Annual Scientific Meeting of the Japanese Circulation Society, Keynote “New Innovations in the Treatment of Heart Failure,” Kobe, Japan, March 15, 2007
- 2007 71st Annual Scientific Meeting of the Japanese Circulation Society, “New Approaches to Heart Failure – from Pharmacogenomics to Drug Development,” Kobe, Japan, March 17, 2007
- 2007 Grand Rounds, “Personalized Medicine in Heart Failure: Fact or Fiction?” Lankenau Hospital, Wynnewood, PA, September 28, 2007
- 2007 Center for Heart Failure Research Symposium, “Genomics and Pharmacogenetics in the treatment of patients with Heart Failure,” Oslo, Norway, October 12, 2007
- 2007 AHA 2007 Scientific Sessions, “Role of Cytokines in the Pathogenesis of Heart Failure, Orlando, FL, November 5, 2007
- 2007 “Personalized Medicine in Heart Failure – Fact or Fiction,” Cardiology Grand Rounds, New York University, New York, NY, November 30, 2007
- 2007 Cellular, Biochemical and Humoral Pathways – Helpful for the Clinician or for the Researcher?, 40th Annual New York Cardiovascular Symposium New York, NY, December 8, 2007



United States Patents:

"Pharmaceutical therapy for congestive heart failure" - #6,221,851, 4/24/01

"Method for quantification of mRNA in endomyocardial biopsies of human heart" - #07/700,651, Filed 5/14/91

"Transgenic mice containing a nucleic acid encoding tumor necrosis factor-under the control of a cardiac specific regulatory region" #5,917,123, Awarded 7/99.

"Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue" awarded 2/00 # 08-933,410.

"Unique polymorphisms in the adenosine receptor genes that predict patient outcomes and therapeutic effectiveness of adenosine agonists" Filed

"Adenosine A1 and A3 Receptor Gene Sequence Variations for Predicting Disease and Treatment Outcome" Filed.

Bibliography:

Peer-Reviewed Manuscripts

1. Feldman, A.M. The effects of 3,3', 5-Triiodo-L-Thyronine on the renal handling of citrate. (Doctoral Dissertation) University Microfilms, Ann Arbor, Michigan (1974).
2. Feldman, A.M. and Grollman, S. The effect of 3,3', 5-Triiodo-L-Thyronine on the renal handling of citrate (38835). *Proc Soc Exp Biol Med*, 149:494-499, 1975.
3. Feldman, A.M. and Brusilow, S.W. Effects of cholera toxin on Cochlear endolymph production: A model for endolymphatic hydrops. *Proc Natl Acad Sci USA*, 73:379-383, 1976.
4. Epstein, M., Feldman, A.M. and Brusilow, S.W. Cerebrospinal fluid production: Stimulation by cholera toxin. *Science*, 196:1012-1013, 1977.
5. Feldman, A.M., Smith, J., Epstein, M.H., Brusilow, S.W. Effects of indomethacin on cholera toxin induced cerebrospinal fluid production. *Brain Res*, 142:379-383, 1978.
6. Brown, R.D. and Feldman, A.M. Pharmacology of hearing and ototoxicity. *Ann Rev Pharmacol Toxicol*, 18:233-252, 1978.
7. Feldman, A.M., Bittner, H.R., Brusilow, S.W. Measurement of the hydrostatic pressures of the cochlear compartments. *Neurological Research*, 1:11-18, 1979.
8. Feldman, A.M., Epstein, M.H., Brusilow, S.W. Effect of cholera toxin and prostaglandins on the rat choroid plexus in vitro. *Brain Res*, 167:119-128, 1979.
9. Feldman, A.M., Epstein, M.H., Maylack, F., Brusilow, S.W. The effect of cholera toxin on choroid plexus carbonic anhydrase activity in vitro. *Neurological Research*, 1:333-339, 1980.

10. Feldman, A.M. and Baughman, K.L. Myocardial infarction associated with a myocardial bridge. *Am Am Heart J*, 111:784-788, 1986.
11. Feldman, A.M., Levine, M.A., Gerstenblith, G., Kaufman, K.D., Baughman, K.L. Negative inotropic effects of furosemide in the isolated rabbit heart: a prostaglandin mediated event. *J Cardiovasc Pharmacol*, 9:493-499, 1987.
12. Feldman, A.M., Guilarte, T.R., Baughman, K.L., Gerstenblith, G. Functional and metabolic consequences of vitamin B-6 deficiency in the rat heart. *Proc Soc Exp Biol Med*, 184:31-39, 1987.
13. Feldman, A.M., Levine M.A., Baughman, K.L., Van Dop, C. NAD⁺-mediated stimulation of adenylate cyclase in cardia membranes. *Biochem Biophys Res Comm*, 142:631-637, 1987.
14. Feldman, A.M., Waber, L.J., DeMent, S.H., Olson, J.L., Baughman, K.L. Plasma carnitine levels in adults with dilated cardiomyopathy. *Heart Failure*, 3:39-44, 1987.
15. Baumgartner, W.A., Augustine, S., Achuff, S.C., Baughman, K.L., Feldman, A.M., Gardner T.J., Traill, T.A., Reitz, B.A. Heart transplantation - The Johns Hopkins Hospital Experience. *Maryland Med J*, 9:751-756, 1987.
16. Feldman, A.M., Fivush, B., Zahka, K.G., Ouyang, P., Baughman, K.L. Congestive cardiomyopathy in patients on continuous ambulatory peritoneal dialysis. *Am J Kidney Dis*, 11:76-79, 1988.
17. Feldman, A.M., Cates, A.E., Veazey W.B., Hershberger, R.E., Bristow, M.R., Baughman, K.L., Baumgartner, W.A., Van Dop, C. Increase of the 40,000-mol pertussis toxin substrate (G protein) in the failing human heart. *J Clin Invest*, 82:189-197, 1988.
18. Feldman, A.M., Becker, L.C., Llewellyn, M.P., Baughman, K.L. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure. *Am Heart J*, 116:771-777, 1988.
19. Witter, F.R., Benedetti, T.J., Petty, B.G., Feldman, A.M., Traill, T.A., Anderson, J. Pharmacodynamics and tolerance of oral sustained released ritodrine. *Am J Obstet. Gynecol*, 159:690-695, 1988.
20. Feldman, A.M., Levine, M.A., Baughman, K.L., Cates, A.E., Van Dop C. Multiple effects of ethanol on cardiac adenylate cyclase. *J Cardiovascular Pharmacol*, 13:774-780, 1989.
21. Feldman, A.M., Cates, A.E., Bristow, M.R., Van Dop C. Altered expression of a-subunits of G proteins in failing human hearts. *J Mol Cell Cardiol*, 21:359-365, 1989.
22. Bristow, M.R., Port, J.D., Sandoval, A.B., Rasmussen, R., Ginsburg, R., Feldman, A.M. β adrenergic receptor pathway in the failing human heart. *Heart Failure*, 5:77-90, 1989.
23. Kessler, P.D., Cates, A.E., Van Dop, C., Feldman, A.M. Decreased bioactivity of the guanine nucleotide-binding protein that stimulates adenylate cyclase (G_s) in hearts from cardiomyopathic syrian hamsters. *J Clin Invest*, 84:244-252, 1989.

24. Bristow, M.R., Port, J.D., Hershberger, R.E., Gilbert, E.M., Feldman, A.M. The β -adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. *Europ Heart J*, 10:45-54, 1989.
25. Newman, K.B., Michael, J.R., Feldman, A.M. Phorbol ester-induced inhibition of the β -adrenergic system in pulmonary endothelium: Role of a pertussis toxin sensitive protein. *Am J Respir Cell Mol Biol*, 1:517-523, 1989.
26. Midei, M.G., DeMent, S.H., Feldman, A.M., Hutchins, G., Baughman, K.L. Peripartum myocarditis and cardiomyopathy. *Circulation*, 81:922-928, 1990.
27. Bristow, M.R., Hershberger, R.E., Port, J.D., Gilbert, E.M., Sandoval, A., Rasmussen, R., Cates, A.E., Feldman, A.M. β -adrenergic pathways in non-failing and failing human ventricular myocardium. *Circulation*, 82:1-12-1-25, 1990.
28. Feldman, A.M., Tena, R.G., Kessler, P.D., Weisman, H.F., Schulman, S.P., Blumenthal, R.S., Jackson, D.G., Van Dop, C. Diminished β -adrenergic receptor responsiveness and cardiac dilatation in hearts of myopathic Syrian hamsters (BIO 53.58) are associated with a functional abnormality of the G stimulatory protein. *Circulation*, 81:1341-1352, 1990.
29. Levine, M.A., Feldman, A.M., Robishaw, J.D., Ladenson, P.W., Ahn, T.G., Moroney, J.F., Smallwood, P.M. Influence of thyroid hormone status on expression of genes encoding G protein subunits in the rat heart. *J Biol Chem*, 265:3553-3560, 1990.
30. Feldman, A.M., Bristow, M.R. The β -adrenergic pathway in the failing human heart: Implications for inotropic therapy. *Cardiology*, 70(suppl. 1):1-32, 1990.
31. Tomaselli, G.F., Feldman, A.M., Yellen, G., Marban E. Human cardiac sodium channels expressed in *Xenopus oocytes*. *Am J Physiol*, 258 (Heart Circ. Physiol. 27):H903-H906, 1990.
32. Connor, D.A., Feldman, A.M., Van Dop, C. cDNA sequence for the α subunit of the guanine nucleotide-binding protein that stimulates adenylyl cyclase (G_{sa}) in syrian hamster heart (*Mesocricetus auratus*). *Nucl Acids Res*, 18:4279, 1990.
33. Hershberger R.E., Feldman A.M., Anderson, F.L., Kimball, J.A., Wynn, J.R., Bristow, M.R. M_r 40,000 and M_r 39,000 pertussis toxin substrate are increased in surgically denervated dog ventricular myocardium. *J Cardiovasc Pharmacol*, 17:568-575, 1991.
34. Feldman, A.M., Jackson, D., Bristow, M.R., Van Dop, C. Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: Discordance with measurements of adenylyl cyclase activity and levels of pertussis toxin substrate. *J Mol Cell Cardiol*, 23:439-452, 1991.
35. Han, R.O., Ray, P.E., Baughman, K.L., Feldman, A.M. Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. *Biochem Biophys Res Commun*, 181:520-523, 1991.

36. Hershberger, R.E., Feldman, A.M., Bristow, M.R. A₁-Adenosine receptor inhibition of adenylate cyclase in failing and non-failing human ventricular myocardium. *Circulation*, 83:1343-1351, 1991.
37. Feldman, A.M. Experimental issues in assessment of G protein function in cardiac disease. *Circulation*, 84:1852-1861, 1991.
38. Feldman, A.M., Ray, P.E., Silan, C.M., Mercer, J.A., Minobe, W., Bristow, M.R. Selective gene expression in failing human heart: Quantification of steady-state levels of mRNA in endomyocardial biopsies using the polymerase chain reaction. *Circulation*, 83:866-1872, 1991.
39. Bristow, M.R., Anderson, F.L., Port, J.D., Skerl, L., Hershberger, R.E., Larrabee, P., O'Connell, J.B., Renlund, D.G., Volkman, K., Murray, J., Feldman, A.M. Differences in β -adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. *Circulation*, 84:1024-1039, 1991.
40. Feldman A.M., Baughman, K.L., Lee, W.K., Gottlieb, S.H., Weiss, J.L., Becker, L.C., Strobeck, J.E. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. *Am J Cardiol*, 68:1203-1210, 1991.
41. Blumenthal, R.S., Flinn, I.W., Proske, O., Jackson, D.G., Tena, R.G., Mitchell, M.C., Feldman, A.M. Effects of chronic ethanol exposure on cardiac receptor-adenylyl cyclase coupling: Studies in cultured embryonic chick myocytes and ethanol fed rats. *Alcohol Clin Exp Res*, 15:1077-1083, 1991.
42. Feldman, A.M., Ray, P.E., Bristow, M.R. Expression of α -subunits of G proteins in failing human heart: A reappraisal utilizing quantitative polymerase chain reaction. *J Mol Cell Cardiol*, 23:1355-1358, 1991.
43. Johns, D.C., Feldman, A.M. Identification of a highly conserved region at the 5' flank of the phospholamban gene. *Biochem Biophys Res Commun*, 188:927-933, 1992.
44. Feldman, A.M. Can we alter survival in patients with congestive heart failure? *JAMA*, 267:1956-1961, 1992.
45. Ladenson, P.W., Sherman, S.I., Baughman, K.L., Ray, P.E., Feldman, A.M. Reversible alterations in a young man with dilated cardiomyopathy and hypothyroidism. *Proc Natl Acad Sci USA*, 82:5251-5155, 1992.
46. Feldman, A.M. Modulation of adrenergic receptors and G transduction proteins in failing ventricular myocardium. *Circulation*, 87:IV-27-IV-34, 1993.
47. Feldman, A.M. Pharmacologic properties and clinical evaluation of the new inotropic agent OPC-8212 (Vesnarinone) *Cardiovasc Drug Rev*, 11:1:1-11, 1993.
48. Feldman, A.M., Weinberg, E.O., Ray, P.E., Lorell, B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. *Circ Res*, 73:184-192, 1993.

49. Feldman, A.M. Classification of positive inotropic agents. *J Am Coll Cardiol*, 22:1223-1227, 1993.
50. Feldman, A.M., Bristow, M.R., Parmley, W.W., Carson, P.E., Pepine, C.J., Gilbert, E.M., Strobeck, J.E., Hendrix, G.H., Powers, E.R., Bain, R.P., White, B.G. for the OPC-8212 Investigators and Coordinators. Effects of Vesnarinone on morbidity and mortality in patients with heart failure: Results of a multi-center trial. *N Engl J Med*, 329:149-155, 1993.
51. Farrukh, H.M., White, M., Port, J.D., Handwerger, D., Larrabee, P., Klein, J., Roden, R.A., Skerl, L., Renlund, D.G., Feldman, A.M., Bristow, M.R. Up-regulation of β_2 -adrenergic receptors in previously transplanted, denervated, nonfailing human hearts. *J Am Coll Cardiol*, 22(7):1902-8, 1993.
52. Bristow, M.R., Minobe, W.A., Port, J.D., Ray, P.E., Feldman, A.M. Reduced β_1 -adrenergic receptor mRNA levels in the failing human heart. *J Clin Invest*, 92:2737-2745, 1993.
53. White, M., Roden, R., Skerl, L., Larrabee, P., Wollmering, M., Port, J.D., Minobe, W.A., Anderson, F., Feldman, A.M., Bristow, M.R. Age-Related changes in the β -adrenergic neuroeffector systems in the human heart. *Circulation*, 90:1225-1238, 1994.
54. Williams, R., Kass, D.A., Kawagoe Y., Pak, P., Tunin, R.S., Shah, R., Hwang, A., Feldman, A.M. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. *Circ Res*, 75:615-623, 1994.
55. Sharir, T., Feldman, M., Haber, H., Feldman, A.M., Marmor, A., Becker, L.C., Kass, D.A. Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power: Validation and non-invasive application. *Circulation*, 89(5):2045-53, 1994.
56. Tomaselli, G.F., Beuckelmann, D.J., Calkins, H.G., Berger, R.D., Kessler, P.D., Lawrence, J.H., Kass, D., Feldman, A.M., Marban, E. Sudden cardiac death in heart failure: the role of abnormal repolarization. *Circulation*, 90:2534-2539, 1994.
57. Loh, E., Barnett, J.R., Feldman, A.M., Couper, G.S., Vatner, D.E., Colucci, W., Galper, J.B. Decreased adenylate cyclase activity and expression of $G_{s\alpha}$ in human myocardium after orthotopic cardiac transplantation. *Circ Res*, 76:852-860, 1995.
58. Feldman, A.M., McNamara, D.M., Rosenblum, W.D., Murali, S. Strategies for Pharmacologic Modulation of the Heart Failure Phenotype. *Clin Card*, 18:IV28-IV35, 1995.
59. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med*, 334:1349-55, 1996.
60. Feldman, M.D., Pak, P.H., Wu, C.C., Haber, H.L., Heesch, C.M., Bergin, J.D., Powers, E.R., Cowart, T.D., Johnson, W.W., Feldman, A.M., Kass, D.A. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure: time and dose dependence analysis based on pressure-volume relations. *Circulation*, 93:474-483, 1996.

61. Packer, M., Colucci, W.S., Sackner-Bernstein, J.D., et al; for the PRECISE Study Group. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure; the PRECISE Trial. *Circulation*, 94:2793-2799, 1996.
62. Premen, Andre J., for the NIH Cardiovascular Aging Advisory Panel. Research Recommendations for Cardiovascular Aging Research. *JAGS*, 44:1114-1117, 1996.
63. Kass, D.A., Van Anden E., Becker L.C., Kasper E.K., White, W.B., Feldman, A.M. Dose-dependence of chronic positive inotropic effect of Vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. *Am J Card*, 78(6):652-6, 1996.
64. Feldman, A.M., Greenhouse P., Sevco MS. Academic cardiology division in the era of managed care: a paradigm for survival. *Circulation*, 95:740-744, 1997.
65. MacGowan, G.A., Mann, D.L., Kormos R.L., Feldman, A.M., Murali, S. Circulating interleukin-6 in severe congestive heart failure. *Am J Cardiol*, 79:1128-1131, 1997.
66. McNamara, D., Alvarez, R.J., Rosenblum, WD, Murali, S., Feldman, A.M. Managing symptomatic heart failure in 1997; Strategies for the end-stage patient. *Int Med*, 18:18-24, 1997.
67. Kubota T., McTiernan C.F., Frye C.S., Demetris A.J., Feldman, A.M. Cardiac specific overexpression of tumor necrosis factor α causes lethal myocarditis in transgenic mice. *J Cardiac Failure*, 3:117-124, 1997.
68. McNamara, D.M., Rosenblum W.D., Janosko K.M., Trost, M.K. Villanueva, F.S., Demetris, A.J., Murali, S., Feldman, A.M. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. *Circulation*, 95:2476-2478, 1997.
69. Kubota T., McTiernan, C.F., Frye, C.S., Demetris, A.J., Feldman, A.M. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor α . *Circ Res*, 81(4):627-635, 1997.
70. McTiernan, C.F., Lemster, B.H., Frye, C., Brooks, S., Combes, A., Feldman, A.M. Interleukin-1 β inhibits phospholamban gene expression in cultured cardiomyocytes. *Circ Res*, 81(4):493-503, 1997.
71. Reis, S.E., Holubkov, R., Edmundowicz, D., McNamara, D.M., Zell, K.A., Detre, K.M., Feldman, A.M. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. *J Am Coll Cardiol*, 30(3):733-8, 1997.
72. Wagner, D.R., Combes, A., McTiernan, Sanders, V.J., Lemster, B.H., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor α . *Circ Res*, 82(1):47-56, 1998.

73. Wagner, D.R., McTiernan, C.F., Sanders, V.J., Feldman, A.M. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. *Circulation*, 97:521-524, 1998.
74. Li, Y-Y, McTiernan, C.F., Frye, C.S., Lemster, B.H., Feldman, A.M. IL-1 β alters the expression of the receptor tyrosine kinase gene r-EphA3 in neonatal rat cardiomyocytes. *Am J Physiol*, 274:H331-H341, 1998.
75. Gorcsan, J., Mandarino, W.A., Feldman, A.M., Kormos, R.L., Batista, R.J.V. Heterogeneous immediate effects of partial left ventriculectomy on cardiac performance. *Circulation*, 97(9):839-842, 1998.
76. Kubota T., Mahler, C.M., McTiernan, C.F., Wu, C.C., Feldman, M.D., Feldman, A.M. End-systolic pressure-dimension relationship of in situ mouse left ventricle. *J Mol Cell Card*, 30(2):357-363, 1998.
77. Lee, J.S., Feldman, A.M. Gene Therapy for therapeutic myocardial angiogenesis: A promising synergism of two emerging technologies. *Nature Medicine*, 4:739-742, 1998.
78. Cohen H.A., Zenati, M.D., Smith, A.J.C., Lee, J.S., Chough S., Jafar, Z., Counihan P.J Izzo, M., Burchenal, J.E., Feldman, A.M., Griffith, B. Feasibility of Combined Percutaneous Transluminal Angioplasty and Minimally Invasive Direct Coronary Artery Bypass in Patients with Multi-vessel Coronary Artery Disease. *Circulation*, 98:1048-1050,1998.
79. Li, Y.Y., Feldman, A.M., Sun, Y., McTiernan, C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. *Circulation*, 98(17):1728-1734,1998.
80. Kubota, T., McNamara, D.M., McTiernan, C.F., Mann, D.L., Trost, M., Holubkov, R., Rosenblum, W.D., Alvarez, R.J., Feldman, A.M. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. *Circulation*, 97(25):2499-501, 1998.
81. Li, Y-Y, McTiernan, C.F., Feldman, A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. *Cardiovascular Research*, 42(1):162-172, 1998.
82. Reis, S.E., Holubkov, R., Zell, K.A., Edmundowicz, D., Shapiro, A.H., Feldman, A.M. Unstable Angina: Specialty-Related Disparities in Implementation of Practice Guidelines. *Clin Cardiol*, 21(3):207-210, 1998.
83. MacGowan, G.A., Kormos, R.L., McNamara, D.M., Alvarez, R.J., Rosenblum, W.D., Pham, S., Feldman, A.M., Murali, S. Predicting short-term outcome in severely ill heart failure patients: Implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. *J of Cardiac Failure*, 4:169-175, 1998.
84. Gorcsan, J., Feldman, A.M., Kormos, R.L., Mandarino, W.A., Demetris, A.J., Batista, R.J.V., Letter to the Editor. Effects of Partial Left Ventriculectomy on Cardiac Performance. *Circulation*, 19:2101-2102, 1998.

85. Cohn, J.N., Goldstein, S., Greenberg, B.H., Lorell, B.H., Bourge, R.C., Jaski, .E., Gottlieb, S.O., McGrew, F., MeMets, D.L., White, B.G., for the Vesnarinone Trial Investigators: Dose-Independent Mortality Increase from Vesnarinone in Severe Heart Failure: The Vesnarinone Trial Results. *N Eng J Med*, 339(25):1810-16, 1998.
86. Wagner, D.R., Kubota, T., Sanders, V.J., McTiernan, C.F., Feldman, A.M. Differential regulation of the cardiac expression of IL-6 and TNF- α by A₂ and A₃ Adenosine Receptor Agonists. *Amer J Physiology*, 276:H2141-H2147, 1999.
87. McTiernan, C.F., Frye, C., Lemster, B., Kinder, E.A., Moravec, C., Feldman, A.M. The Human Phospholamban Gene: Structure and Expression. *J Mol Cell Cardiology*, 31:679-692,1999.
88. Bozkurt, B., Villanueva, F.S., Tokarczyk, T., Holubkov, R., Alvarez, R.J., MacGowan, G.A., Murali, S., Rosenblum, W.D., Feldman, A.M., McNamara, D.M. Intravenous Immune Globulin in the therapy of peripartum cardiomyopathy. *J Am Coll Cardiol*, 34:177-80, 1999.
89. McTiernan, C.F., Lemster, B.H., Frye, C.S., Johns, D.C., Feldman, A.M. Characterization of proximal transcription regulatory elements in the rat phospholamban promoter. *J Mol Cell Cardiol*, 31:2137-53, 1999.
90. Writing Group, 30th Bethesda Conference. The Future of Academic Cardiology. *J Am Coll Cardiol*, 33(5):1092-1135, 1999.
91. Soran, O., Young, J.D., Loftus, S., Bourge, R., Carson, P., Jaski, B., Holubkov, R., Feldman, A.M. for the VEST Withdrawal Substudy Group. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: Results of the vesnarinone trial withdrawal sub-study. *J of Cardiac Failure*, 5(3):195-200, 1999.
92. Packer, M., Cohn, J.N. on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. *Am J Cardiol*, 83:2A-38A, 1999.
93. Adams, K.F., Baughman, K.L., Dec, W.G. et al. HFSA clinical practice guideline update for the management of patients with heart failure due to left ventricular systolic dysfunction: Pharmacologic approaches. (A report of the Guidelines Committee and the Executive Council of the HFSA). *J Card Failure*, 5(4):357-382,1999.
94. Soran, O., Crawford, L.E., Schneider, V.M., Feldman, A.M. Enhanced External Counterpulsation in the Management of Patients with Cardiovascular Disease. *Clinical Cardiology*, 22:173-178, 1999.
95. Feldman, A.M., Wagner, D.R., McNamara, D.M. AMPD1 Gene Mutation in Congestive Heart Failure: New insights into the Pathobiology of Disease Progression. *Circulation*, 99(11):1397-1399, 1999.
96. Kubota, T., Bounoutas, G.S., Miyagishima, M., Kadokami, T., Sanders, V.J., Bruton, C., Robbins, P.D., McTiernan, C.F., Feldman, A.M. Soluble tumor necrosis factor receptor

- abrogates myocardial inflammation but not hypertrophy in transgenic mice with cytokine-induced cardiomyopathy. *Circulation*, 101:2518-25, 2000.
97. Feldman, A.M., Combes, A., Wagner, D., Kadakomi, T., Kubota, T., Li, Y.Y., McTiernan, C.F. The role of tumor necrosis factor in the pathophysiology of heart failure. *J Am Coll Cardiol*, 35:537-44, 2000.
 98. Soran, O., Feldman, A.M., Cohen, H.A. The oculostenotic reflex and iatrogenosis fulminans. *Circulation*, 101:E198-E199, 2000.
 99. Li, Y.Y., McTiernan, C.F., Feldman, A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. *Cardiovascular Res*, 46:214-24, 2000.
 99. Feldman, A.M., Lorrell, B., Reis, S. Trastuzumab in the treatment of metastatic breast cancer: anti-cancer therapy vs. cardiotoxicity. *Circulation*, 102:272-274, 2000.
 100. Reis, S.E., Holubkov, R., Young, J.B., White, B.G., Cohn, J.N., Feldman, A.M. Estrogen is associated with improved survival in women with congestive heart failure: analysis of the Vesnarinone studies. *J Am Coll Card*, 36:529-33, 2000.
 101. Kadokami, T., McTiernan, C.F., Kubota, T., Frye, C.S., Feldman, A.M. Sex-related differences in murine cardiomyopathy are associated with differences in tumor necrosis factor-receptor expression. *J Clin Invest*, 106:589-97, 2000.
 102. Kubota, T., Miyagishima, M., Alvarez, R.J., Kormos, R., Rosenblum, W.D., Demetris, A.J., Semigran, M.J., Dec, G.W., Holubkov, R., McTiernan, C.F., Mann, D.L., Feldman, A.M., McNamara, D.M. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. *J Heart Lung Transplant*, 19:819-24, 2000.
 103. Feldman, A.M., McNamara, D. Medical Progress: Myocarditis. *N Eng J Med*, 343:1388-98, 2000.
 104. Bristow, M.R., Feldman, A.M., Saxon, L.A., for the COMPANION Steering Committee and COMPANION Clinical Investigators. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION) Trial. *J Card Failure*, 6:276-85, 2000.
 105. Li, Y.Y., Feng, Y.Q., Kadokami, T., McTiernan, C.F., Draviam, R., Watkins, S., Feldman, A.M. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor- α can be modulated by anti-tumor necrosis factor- α therapy. *Proc. Natl Acad Sci*, 97:12746-51, 2000.
 106. Stevenson, L.W., Kormos, R.L. Barr, M.L., Costanzo, M.R., Desvigne-Nickens, P., Feldman, A.M., Frazier, O.H., Friedman, L., Hill, J.D., Konstam, M.A., McCarthy, P.M., Michler, R.E., Oz, M.C., Rosengard, B.R., Sapirstein, W., Shanker, R., Smith, C.R., Starling, R.C., Taylor, D.O., Wichman, A. Mechanical Cardiac Support 2000: Current Applications and Future Trial Design: June 15-16, 2000 Bethesda, MD. *J Am Coll Card*, 37:340-370, 2001.

107. Stevenson, L.W., Kormos, R.L., Bourge, R.C., Gelijns, A., Griffith, B.P., Hershberger, R.E., Hunt, S., Kirklin, J., Miller, L.W., Pae, W.E. Jr., Pantalos, G., Pennington, D.G., Rose, E.A., Watson, J.T., Willerson, J.T., Young, J.B., Barr, M.L., Costanzo, M.R., Desvigne-Nickens, P., Feldman, A.M., Frazier, O.H., Friedman, L., Hill, J.D., Konstam, M.A., McCarthy, P.M., Michler, R.E., Oz, M.C., Rosengard, B.R., Sapirstein, W., Shanker, R., Smith, C.R., Starling, R.C., Taylor, D.O., Wichman, A. Mechanical Cardiac Support 2000: Current Applications and Future Trial Design: June 15-16, 2000 Bethesda, MD. *Circulation*, 103:337-342, 2001.
108. Bozkurt, B., Torre-Amione, G., Warren, M.S., Whitmore, J., Soran, O., Feldman, A.M., Mann, D.L. Results of targeted anti-TNF therapy with Etanercept (ENBREL) in patients with advanced heart failure. *Circulation*, 103:1044-1047, 2001.
109. McNamara, D.M., Holobkuv, R., Janosko, K., Palmer, A., Wang, J.J., MacGowan, G.A., Murali, S., Rosenblum, W.D., London, B., Feldman, A.M. Pharmacogenetic interactions between beta blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. *Circulation*, 103:1644-1648, 2001.
110. Soran, O., Feldman, A.M., Schneider, V.M., Hanna, R., Mann, D.L., Korth-Bradley, J.M. The pharmacokinetics of etanercept in patients with heart failure. *Br J Clin Pharmacol*, 51:191-192, 2001.
111. Sutton-Tyrrell K., Kuller, L.H., Edmundowicz, D., Feldman, A., Holubkov, R., Givens, L., Matthews, K.A., Usefulness of electron beam tomography to detect progression of coronary and aortic calcium in middle-aged women. *Am J Cardiol* 2001 Mar 1, 87(5):560-4.
112. Lawson, W.E., Kennard, E.D., Holubkov, R., Kelsey, S.F., Strobeck, J.E., Soran, O., Feldman, A.M. for the IEPR investigators. Benefit of safety of enhanced external counterpulsation in treating coronary artery disease patients with a history of congestive heart failure. *Cardiology*, 96:78-84, 2001.
113. Feldman, A.M., Li, Y.Y., McTiernan, C.F. Matrix metalloproteinases in the pathophysiology and treatment of heart failure. *Lancet*, 357:654-5, 2001.
114. Kadokami, T., McTiernan, C.F., Kubota, T., Frye, C.S., Bounoutas, G.S., Robbins, P.D., Watkins, S.C., Feldman, A.M. Effects of soluble tumor necrosis factor receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. *Am J Phys Circ Physiol*, 280: H2281-H2291, 2001.
115. Deswal, A., Petersen, N. J., Feldman, A.M., Young, J.B., White, B.G., Mann, D.L. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). *Circulation*, 103:2055-2059, 2001.
116. McNamara, D.M., Holobkuv, R., Starling, R.C., Dec, G.W., Loh, E., Guillermo, T.A., Gass, A., Janosko, K., Tokarczyk, T., Mann, D.L., Feldman, A.M. for the IMAC Investigators. Controlled Trial of intravenous immune globulin in recent onset dilated cardiomyopathy. *Circulation*, 103:2254-2259, 2001.
117. Barsness, G., Feldman, A.M., Holmes, D., Holubkov, R., Kelsey, S.F., Kennard, E. The International EECF Patient Registry (IEPR): Design, methods, baseline characteristics, and acute results. *Clinical Card*, 24:435-442, 2001.

118. Combes, A., McTiernan, C., Brooks, S.S., Feldman, A.M. UV light synergistically enhances the cardiotoxic effects of IL-1 β through peroxynitrite formation. *J Card Failure*, 7:165-175, 2001.
119. Kubota, T., Miyagishima, M., Bounoutas, G.S., Kadokami, T., Watkins, S.C., McTiernan, C.F., Feldman, A.M. Overexpression of tumor necrosis factor- α activates both anti and pro-apoptotic pathways in the myocardium. *J Mol Cell Cardiol*, 33:1331-1344, 2001.
120. Kadokami, T., Frye, C., Lemster, B., Wagner, C.L., Feldman, A.M., McTiernan, C.F. Anti-TNF α antibody limits heart failure in a transgenic model. *Circulation*, 104:1094-1097, 2001.
121. Li, Y.Y., Feng, Y., McTiernan, C.F., Moravec, C.S., Kormos, R.L., Watkins, S.C., Feldman, A.M. Downregulation of matrix metalloproteinases and reduced collagen damage in the failing human heart after support with left ventricular assist devices. *Circulation*, 104:1147-1152, 2001.
122. Deswal, A., Peterson, N.J., Feldman, A.M., White, B.G., Mann, D.L. Effects of Vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: A Report from the Vesnarinone Trial (VEST). *Chest*, 120:453-459, 2001.
123. Li, Y.Y., Feldman, A.M. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. *Drugs*, 61:1239-1252, 2001.
124. Li, Y.Y., Chen, D., Kadokami, T., Watkins, S.C., Feldman, A.M. Mitochondrial abnormalities in tumor necrosis factor alpha induced heart failure are associated with impaired DNA repair activity. *Circulation*, 104:2492-7, 2001.
125. Li, Y.Y., Mi, Z., McTiernan, C.F., Robbins, P.D., Feldman, A.M. Differential Effects of overexpression of two forms of Ephrin-A5 on neonatal rat cardiomyocytes. *Am J Physiol*, 281:H2738-H2746, 2001.
126. Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., Ganiats, T.G., Goldstein, S., Gregoratos, G., Jessup, M.L., Noble, R.J., Packer, M., Silver, M.A., Stevenson, L.W., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol*, 38:2101-13, 2001.
127. Beller, G.A., Bonow, R.O., Fuster, V. et al. ACC Revised Recommendations for Training in Adult Cardiovascular Medicine Core Cardiology Training II (COCATS 2) (Revision of the 1995 COCATS Training Statement). *J Am Coll Cardiol*, 39:1242-6, 2002.
128. Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., Ganiats, T.G., Goldstein, S., Gregoratos, G., Jessup, M.L., Noble, R.J., Packer, M., Silver, M.A., Stevenson, L.W., Gibbons, R.J., Antman, E.M., Alpert, J.S., Faxon, D.P., Fuster, V., Gregoratos, G., Jacobs, A.K., Hiratzka, L.F., Russell, R.O., Smith, S.C. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *J Heart Lung Transplant*, 21:189-203, 2002.

129. Li Y.Y., Kadokami T., Wang, P., McTiernan, C.F., Feldman, A.M. Matrix metalloproteinase inhibition modulates TNF alpha transgenic mouse phenotype early in the development of heart failure. *Am J Physiol Heart Circ Physiol*, 282:H983-9, 2002.
130. Feldman, A.M., McNamara, D.M. Re-evaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. *Clin Cardiol*, 25:256-62, 2002.
131. Shusterman, V., Usiene, I., Harrigal, C., Lee, J.S., Kubota, T., Feldman, A.M., London, B. Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. *AJP: Heart and Circulatory Physiol*, 282:H2076-H2083, 2002.
132. Funakoshi, H., Kubota, T., Kawamura, N., Machida, Y., Feldman, A.M., Tsutsui, H., Shimokawa, H., Takeshita, A. Disruption of inducible nitric oxide synthase improves β -adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. *Circ Res*, 90:959-65, 2002.
133. Funakoshi, H., Kubota, T., Machida, Y., Kawamura, N., Feldman, A.M., Tsutsui, H., Shimokawa, H., Takeshita, A. Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor- α . *Am J Physiol, Heart Circ Physiol*, 282(6):H2159-66, 2002.
134. Soran, O., Kennard, E.D., Kelsey, S.F., Holubkov, R., Strobeck, J., Feldman, A.M. Enhanced External Counterpulsation as Treatment for Chronic Angina in Patients with Left Ventricular Dysfunction: A report from the International EECF Patient Registry (IEPR). *Congest Heart Fail*, 8(6):297-302, 2002.
135. Frye, R.F., Schneider, V.M., Frye, C.S., Feldman, A.M. Plasma levels of TNF- α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. *J Card Fail*, 8(5): 315-9, 2002.
136. Combes, A., Frye, C.S., Lemster, B.H., Brooks, S.S., Li, Y.Y., Watkins, S.C., Feldman, A.M., McTiernan, C.F. Chronic exposure to IL-1 β but not TNF α or IL-6 induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. *Cytokine*, 445(2):246-56, 2002.
137. London, B., Baker, L., Lee, J.S., Shusterman, V., Choi, B.R., Kubota, T., McTiernan, C.F., Feldman, A.M., Salama, G. Calcium-dependent arrhythmias in transgenic mice with heart failure. *Am J Physiol, Heart Circ Physiol*, 284(2): H431-41, 2003
138. McNamara, D.M., Holubkov, R., Postava, L., Ramani, R., Janosko, K., Mathier, M., MacGowan, G.A., Murali, S., Feldman, A.M., London, B. Effect of the he Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. *Circulation*, 107 (12): 1598-602, 2003.
139. Machida, Y., Kubota, T., Kawamura, N., Funakoshi, H., Ide, T., Utsumi, H., Li, Y.Y., Feldman, A.M., Tsutsui, H., Shimokawa, H., Takeshita, A. Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium. *Am J Physiol Heart Circ Physiol*, 284(2): H449-55, 2003.

140. Gottipaty, V.K., Krelis, S.P., Weiss, R., Shusterman, V., Saba, S., Anderson, K.P., White, B.G., Feldman, A.M., for the VEST Investigators. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. *Circulation*, In revision.
141. Janczewski, A.M., Kadokami, T., Lemster, B., Frye, C.S., McTiernan, C.F., Feldman, A.M. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF- α . *Am J Physiol Heart Circ Physiol*. 284(3): H960-9, 2003.
142. Feldman, A.M. Enhanced external counterpulsation: Mechanism of action. *Clin Card*, 25 (Suppl. II), 11-15, 2002.
143. Frye, R.F., Schneider, V.M., Frye, C.S., Feldman, A.M. Plasma levels of TNF- α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. *J Cardiac Failure*, 8(5): 315-319, 2002.
144. Soran, O., Fleishman, B., Demarco, T., Grossman, W., Schneider, V.M., Manzo, K., de Lame, P.A., Feldman, A.M. Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility study. *Congestive Heart Failure*, 8(4): 204-210, July/August, 2002.
145. McGowan B.S., Ciccimaro E.F., Chan, T.O., Feldman, A.M. The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardium. *Cardiovascular Toxicology*, 3(3):191-206, 2003.
146. Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D., DeMarco, T., Carsom, P., DiCarlo, L., DeMets, D., White, B.G., De Vries, D.W., Feldman, A.M. Cardiac Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure: The COMPANION Trial. *New Engl J Med*, 2003 May 20, 350(21):2140-50.
147. Fye, WB, Hirshfeld, JW, et al. Cardiology's workforce crisis: a pragmatic approach. Presented at the 35th Bethesda Conference, Bethesda, MD, October 17-18, 2003. *J Am Coll Cardiol* 2004; 44; 215-75.
148. Bristow, M.R., Feldman, A.M., Adams, Jr., Kirkwood F., Goldstein, S. Selective v. Non-selective β -Blockade for Heart Failure Therapy: Are There Lessons to be Learned from the COMET Trial? *J. Cardiac Fail*, 2003 Dec, 9(6): 444-453.
149. Feldman, A.M., Klein, H., Tchou, P., Murali, S. Mancini, D., Boehmer, J., Harvey, M., Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of WEARIT/BIOROAD. *Pacing Clin Electrophysiol*. 2004 Jan, 27(1), 4-9.
150. Giles, T.D., Chatterjee, K., Cohn, J.N., Colucci, W.S., Feldman, A.M., Ferrans, V.J., Roberts, R. Definition, Classification, and Staging of Adult Cardiomyopathies: A Proposal for Revision, *J. Card. Fail.* 2004 Feb, 10(1): 6-8.
151. Feldman, A.M., McTiernan, C., Is There Any Future for Tumor Necrosis Factor Antagonists in Chronic Heart Failure, *Am J. Cardiovasc Drugs* 2004, 4(1), 11-9.

152. Tang, Z., McGowan, B.S., Huber, S.A., McTiernan, C.F., Addya, S., Surrey, S., Kubota, T., Fortina, P., Higuichi, Y., Diamond, M., Wrye, D.S., Feldman, A.M., Gene Expression profiling during the transition to failure in TNF- α over-expressing mice demonstrates the development of autoimmune myocarditis, *J. Mol. and Cell. Cardiol*, 2004 Apr, 36(4):515-30
153. Higuchi, Y., McTiernan, C.F., Frye, C.B., McGowan, B.S., Chan, T.O., Feldman, A.M., Tumor Necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. *Circulation*, 2004 Apr 20, 109(15), 1892-7.
154. Mann, D.L., McMurray, J., Packer, M., Swedberg, K., Borer, J.S., Colucci, W.S., Djian, J., Drexler, H., Feldman, A.M., Kober, L., Krum, H., Liu, P., Niemenen, M., Tavazzi, L., van Veldhuisen, D. J., Waldenstrom, A., Warren, M., Westheim, A., Zannad, F., Fleming, T. Targeted Anti-Cytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (Renewal). *Circulation*, 2004 Apr 6, 109(13), 1594-602.
155. Janczewski, A.M., Zahid, M., Lemster, B.H., Frye, C.S., Gibson, G., Higuchi, Y., Kranias, E.G., Feldman, A.M., McTiernan, C.F., Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model, *Cardiovascular Research*, 2004 Jun 1, 62(3), 468-80.
156. Baughman, K.L., Pepine, C.J., Abrams, J., Bashore, T.M., Califf, R.M., Feldman, A.M., Fye, W.B., Griffin, B.P., Myerburg, R.J., Naccarelli, G.V., Williams, E.S., Working Group 1: How to Increase the Output of Cardiologists, *J Am Coll Cardiol*, 2004 July 21:44(2): 233-7.
157. Ramani, R., Mathier, M., Wang, P., Gibson, G., Togel, S., Dawson, J., Bauer, A., McTiernan, C., Feldman, A.M. Inhibition of tumor necrosis factor- α receptor-1 mediated pathways has beneficial effects in a murine model of post-ischemic remodeling. *Amer. J of Physiol/Heart Circ Physiol*, 2004 Sep; 287(3): H1369-77.
158. Ramani, R., Mathier, M., Dawson, J., McTiernan, C.F., Feldman, A.M., Assessment of Infarct Size and Myocardial Function in Mice Using Transepophageal Echocardiography, *J. Amer. Soc. Of Echocardiography*, 2004; 17(6), 649-653.
159. McNamara DM, Holubkov R, Postava L, Janosko K, Macgowan GA, Mathier M, Murali S., Feldman AM, London B; Pharmacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. *J Am Coll Cardiol*, 2004 Nov 16:44(10): 2019-26.
160. Bristow, M.R., Adams Jr., KF, Bauman, J.L., Feldman, A.M., Giles, T.D., Goldstein, S., Mann, D.L., Talbert, R.L., The COMET Trial, *Cong. Heart Fail.* Jan/Feb 2005: 11(1): 39-47.
161. Feldman A.M., Protecting the Integrity of Clinical Trials in the Digital Age. *J Card Fail.* 2005 Feb, 11(1): 7-8.
162. Feldman, A.M., Silver, M.A., Francis, G., deLame, P.A., Parmley, W.W., Treating Heart Failure with Enhanced External Counterpulsation (EECP): Design of the Prospective Evaluation of EECP in Heart Failure (PEECH) Trial, *JCard Fail*, 2005 Apr, 11(3): 240-5.

163. Kadokami, T., McTiernan, C.F., Higuichi, Y., Frye, C.S., Kubota, T., Feldman, A.M., 17 β -Estradiol Improves Survival in Male Mice with Cardiomyopathy Induced by Cardiac-Specific Tumor Necrosis Factor- α Overexpression, *J of Interferon & Cytokine Res.*, 2005 May, 25(5): 254-60.
164. Kawanura, N., Kubota, T, Kawana, S., Monden, Y., Feldman, A.M., Tsutsui, H., Takeshita, A., Sunagawa, K. Blockade of NR- κ B Improves Cardiac Function and Survival without affecting Inflammation in TNF- α -induced Cardiomyopathy. *Cardiovasc Res*, 2005, Jun 1; 66(3): 520-529.
165. Al-Khatib S.M., Sanders G.D., Mark D.B., Lee K.L., Bardy G.H., Bigger J.T., Buxton A.E., Connolly S., Kadish A., Moss A., Feldman A.M., Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. *Am Heart J.* 2005 Jun, 149(6): 1020-34.
166. Brown, M., McGuinness, M., Wright, T., Ren, X., Wang, Y., Boivin, G.P., Hahn, H., Feldman, .M., Jones, W.K., Cardiac-Specific Blockade of NF- κ B In Cardiac Pathophysiology: Differences between Acute and Chronic Stimuli In Vivo, *Am. J. Physiol/Heart-Circ Physiol*, 2005 Jul, 289(1): H466-476.
167. Sheppard, R, Bedi, Maninder, Kubota, T, Semigran, M.J., Dec, G.W., Holubkov, R, Feldman, A.M., Rosenblum, W.D., McTiernan, C.F., McNamara, D.M., Myocardial Expression of Fas and Recovery of Left Ventricular Function in Patients with Recent-onset Cardiomyopathy, *J Am Coll Cardiol*, 2005 Sep 20;46(6): 1036-42.
168. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, Jr., C.W., et al. ACC/AHA Guideline Update for the Diagnosis and
169. Management of Chronic Heart Failure in the Adult, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, *Circulation*, 2005 Sep 20;112 (12): e154-235.
170. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., Antman, E.M., Smith, S.C. Jr., Adams, C.D., Anderson, J.L., Faxon, D.P., Fuster, V., Halperin, J.L., Hiratzka, L.F., Hunt, S.A., Jacobs, A.K., Nishimura, R., Ornato, J.P., Page, R.L., Riegel, B., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult – Summary Article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines : Developed in Collaboration with the American Colleger of Chest Physicians and the Int'l Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society; *Circulation*, 2005 Sept 20: 112(12) 1825-1852.
171. Saba S., Janczewski A.M., Baker L.C., Shusterman V., Gursoy E.C., Feldman A.M., Salama G., McTiernan C.F., London B., Atrial Contractile Dysfunction, Fibrosis, and Arrhythmias in a Mouse Model of Cardiomyopathy Secondary to Cardiac-Specific Overexpression of TNF- α , *Am J Physiol Heart Circ Physio.* 2005 Oct; 289(4): H1456-67.

172. Matsusaka, H., Ikeuchi, M., Matshshima, S., Ide, T., Kubota, T., Feldman, A.M., Takeshita, A., Sunagawa, K., Tsutsui, H. Selective Disruption of MMP-2 Gene Exacerbates Myocardial Inflammation and Dysfunction in Mice with Cytokine-Induced Cardiomyopathy, *Am J Physiol/Heart Circ Physiol*, 2005, Nov; 289(5): H1858-1864.
173. Carson, P., Anand I., O'Connor, C., Jaski B., Steinberg J., Lwin A., Lindenfeld J., Ghali J., Barnet, J.H., Feldman, A.M., Bristow, M., Mode of Death in Advanced Heart Failure – The Comparison of Medical, Pacing and Defibrillation Therapies in Heart Failure (COMPANION) Trial, *J Am Coll Cardiol*, 2005 Dec; 46, 2329-2334.
174. Feldman, A.M., Benz, E.J. Restructuring the Academic Department of Internal Medicine. *Am J. Med.* 2005 Dec: 118(12): 1430-5.
175. Feldman, A.M., deLissovoy, G., Bristow, M.R., Saxon, L.A., DeMarco, T., Kass, D.A., Boehmer, J., Singh, S., Whellan, D.J., Carson, P., Boscoe, A., Baker, T., Gunderman, M., Cost-Effectiveness of Cardiac-Resynchronization Therapy in the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial, *J Am Coll Cardiol*, 2005 Dec; 46(12): 2311-2321.
176. Lowes, B.D., Shakar, S.F., Metra, M., Feldman, A.M., Eichhorn, E., Gerber, M.J., Liard, J., Hartman, C., Gorczynski, R., Evans, G., Linseman, J.V., Stewart, J., Robertson, A.D., Roecker, E.B., DeMets, D.L., Bristow, M.R., Rationale and Design of Enoximone Clinical Trials Program, *J Card Fail* 2005 Dec; 11(9): 659-69.
177. Higuchi, Y., Chan, T.O., Brown, M.A., Zhang, J., DeGeorge, Jr., B.R., Funakoshi, H., Gibson, G., McTiernan, C.F., Kubota, T., Jones, W.K., Feldman, A.M., Cardioprotection Afforded by NF- κ B Ablation is Associated with Activation of Akt in Mice Over-Expressing TNF α , *Amer J of Physiol/Heart Circ Physiol*, 2006 Feb, 290(2), H590-8; epub 2005 Sep 30.
178. Feldman, A.M., Weitz, H., Merli, G., DeCaro, M., Brechbill, A.L., Adams, S., Bischoff, L., Richardson, R., Williams, M.J., Wenneker, M., Epstein, A. The Physician-Hospital Team: A Successful Approach to Improving Care in a large Academic Medical Center, *Acad Med*, 2006 Jan; 81(1): 35-41.
179. Most, P., Seifer, H., Gao, E., Funakoshi, H., Volkens, M., Heierhorst, J., Pleger, S.T., DeGeorge, B., Remppis, A., Feldman, A.M., Katus, H.A., Koch, W.J., Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction, *Circulation*, 2006 Sep 19; 114(12): 1258-68; epub 2006 Sep 4.
180. McNamara, D.M., Tam, S.W., Sabolinski, M., Tobelman, P., Janosko, K., Palmer, A., Tayler, A., Feldman, A.M., Worcel, M., Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African-Americans with Heart Failure: Results from the AheFT Trial, *J Am Coll Cardiol*, 2006 Sep 19 (48) 6, 1277-1282.
181. Feldman, A.M., Silver, M.A., Francis, G.S., Abbottsmith, C.W., Fleishman, B.L., Soran, O., deLame, P.A., Varricchione, T., Enhanced External Counterpulsation Improves Exercise Tolerance in Patients with Chronic Heart Failure (PEECH), *J Am Coll Cardiol*, 2006 Sept 19 (48) 6, 1198-1205.
182. Marik, P.E., Stauffer, R., Anto, S., McNichol, M., Feldman, A.M., An Intranet-based system for inpatient billing in an Academic Medical Center, *Am J. Med.* 2006; 119 (8): 647-50.

183. Saxon, L.A., Bristow, M.R., Boehmer, J., Krueger, S., Kass, D.A., DeMarco, T., Carson, P., DiCarlo, L., DeMets, D., Feldman, A.M., Predictors of Sudden Cardiac Death and Appropriate Shock in the COMPANION Trial, *Circulation*, 2006 Dec 9; 114 (25): 2766-72. Epub 2006 Dec 11.
184. Lindenfeld, J., Feldman, A.M., Saxon, L., Boehmer, J., Carson, P., Ghali, J., Anand, I., Singh, Steinberg, J., Jaski, B., DeMarco, T., Mann, D., Yong, P. Galle, E., Ecklunc, Bristow, M., Cardiac Resynchronization Therapy with or without a Defibrillator Improves Survival and Hospitalizations in Patients with NYHA Class IV Heart Failure, *Circulation*, 2007; 115: 204-12.
185. Huber, S.A., Feldman, A.M., Sartini, D., Coxsackievirus B3 Induces T Regulatory Cells which Inhibit Cardiomyopathy in TNF Transgenic Mice, *Circulation Research*, 2006 99(10):1109-16. Epub 2006 Oct 12.
186. Funakoshi, H., Chan, T.O., Good, J.C., Lee, L.L., Herrmann, D.E., Zhang, J., Orange, Orange, M., Palmer, T.M., Sanbe, A., Robbins, J., Koch, W.J., Feldman, A.M., Regulated Overexpression Of The A1 Adenosine Receptor in Mice Results In Adverse But Reversible Changes In Cardiac Morphology and Function, *Circulation*, 2006 Nov 21; 114(21): 2240-50.
187. Abbottsmith, C.W., Chung, E.S., Varricchione, T., de Lame, P.A., Silver, M.A., Francis, G.S., Feldman, A.M. Enhanced External Counterpulsation Improves Exercise Duration and Peak Oxygen Consumption in Older Patients with Heart Failure: A Subgroup Analysis of the PEECH Trial, *Cong Heart Fail*, 2006 Nov-Dec; 12(6): 307-11.
188. Marelli, D., Silvestry, S.C., Zwas, D., Mather, P., Rubin, S., Dempsey, A.F., Stein, L., Rodriguez, E., Diehl, J.T., Feldman, A.M., Modified inferior vena caval anastomosis to Reduce tricuspid valve regurgitation after heart transplantation. *Tex Heart Inst J.*, 2007; 34(1): 30-5.
188. Feldman, A.M., Force, T., Koch, W.J., Lost in Translation: Failure of Industry and federal regulatory agencies to utilize translational research in drug discovery decision-making, *Clin Pharmacol Ther.* 2007 Jun;81(6):887-92. Epub 2007 Mar 28.
190. Mark, G.E., Rhim, E.S., Feldman, A.M., Pavir, B.B., Cardiac Resynchronization Therapy: from creation to evolution-an evidence-based review., *Congest Heart Fail.*, 2007 Mar-Apr; 13(2): 84-92.
191. Gao, X., Xu, X., Belmadani, S., Park, Y., Tang, Z., Feldman, A.M., Chilian, W.M., Zhang, C., TNF- alpha Contributes to Endothelial Dysfunction by Upregulation Arginase in Ischemia/Reperfusion Injury, *Atheroscler Thromb Vasc Biol.* 2007 Jun;27(6):1269-75. Epub 2007 Apr 5.
192. Funakoshi, H., Zacharia, L.C., Tan, Z., Zhang, J., Lee, L.L., Good, J.C., Herrmann, D.E., Higuchi, Y., Koch, W.J., Jackson, E.K., Chan, T.O., Feldman, A.M., A₁ Adenosine receptor Up-Regulation Accompanies Decreasing Myocardial Adenosine Levels in Mice with Left Ventricular Dysfunction, *Circulation*, 2007 May 1; 115(17):2307-15. Epub 2007 Apr 16.

193. Mann, D.L., Bozkurt, B., Torre-Amione, G., Soran, O.Z., Feldman, A.M., Sivasubramanian, N., Effect of Etanercept, A Soluble TNF Antagonist, on Tumor Necrosis Factor Bioactivity and Stability, *CTS*, in press.
194. Velazquez, E.J., Lee, K.L., O'Connor, C.M., Oh, J.K., Bonow, R.O., Pohost, G.M., Feldman, A.M., Mark, D.B., Panza, J.A., Sopko, G., Rouleau, J., Jones, R.H., for the STITCH Investigators, The Rationale and Design of the Surgical Treatment for Ischemic Heart Failure (STITCH) Trial, *J. of Thoracic and Cardiovascular Surgery*, 2007 Dec, 134(6), 1540-1547.
195. Cooper, L.T., Baughman, K., Brutsaert, D.L., Feldman, A.M., Frustaci, A., Jessup, M., et al., AHA/ACC/ESC Joint Scientific Statement, The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease, *Circulation*, J Am Coll Cardiol 2007 Nov 6; 50(19:1914-41) .
195. Feldman, A.M., Oren, R.M., Abraham W.T., Boehmer, J.P., Carson, P.E., Eichhorn E., et al. for the EMOTE Study Group, Low Dose Oral Enoximone Enhances the Ability to Wean Patients with Ultra-Advanced Heart Failure from Intravenous Inotrope Support: Results from the Oral Enoximone in Intravenous Inotrope-Dependent Subjects (EMOTE) Trial, *Am Heart J* 2007 Nov; 154(5:861-9).
196. Tang Z, Diamond MA, Chen J-M, Holly T.A., Bonow R.), Dasgupta A., Hyslop T., Purzycki A, Wagner, J, McNamara, D.M., Velazquez E.J., Ardlie, K., Feldman A.M., Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy. *Clin Pharm Therap* 2007 Oct; 82(4:435-40).
197. Ghali, J.K., Boehmer, J., Feldman, A.M., Saxon, L.A., DeMarco, T., Carson, P., Yong, P., Galle, E., Leigh, J., Ecklund, F.L., Bristow, M.R., Influence of Diabetes on Cardiac Resynchronization Therapy with or without Defibrillator in Patients with Advanced Heart Failure, *J Cardiac Failure*, J Card Fail 2007 Nov; 13(9:769-73).
198. DeMarco, T., Leigh, J., Ghali, J.K., Boehmer, J., Mann, D., Saxon, L.A., Bristow, M.R., Wagonle, E., Lowes, B., Wolfel, G., Goel, S., Impact of Cardiac Resynchronization Therapy on Exercise Performance, Functional Capacity and Quality of Life in Systolic Heart Failure with QRS Prolongation: COMPANION Trial Sub-Study, *J. Cardiac Failure*, J Card Fail 2008 Feb;14 (1;9-18).
199. Wagner, D.R., Counihan, P.J., Crawford, L., Izzo, M., Lee, J.S., Smith, A.J.C., Jafar, M.Z., Katz, W., Rosenfelder, D., Feldman, A.M., Cohen, H.A. High Dose Intracoronary Adenosine Improves Coronary Blood Flow During Primary Angioplasty of Anterior Wall Infarcts, submitted.
200. Gottipaty, V.K., Krelis, S.P., Weiss, R., Shusterman, V., Saba, S., Ganz, L.I., Anderson, K.P., White, B.G., Feldman, A.M. for the Vesnarinone Investigators. Atrial fibrillation is associated with increased mortality in patients with cardiomyopathies and class III-IV heart failure. *J Am Coll Cardiol*, submitted.
201. Wen, S., Janczewski, A.M., Stabenow, K.E., Lemster, B.H., Feldman, A.M., McTiernan, C.F. A phosphorine-mimetic phospholamban mutant enhances calcium transients in cardiomyocytes. *Circulation*, submitted.
202. Sumner, A.D., Boehmer, J.P., Saxon, L.A., Feldman, A.M., Bristow, M.R., Statin Use Is



Associated with Marked Improvement in Survival in an Advanced Heart Failure Population from the COMPANION Trial, submitted.

203. Richardson R., Adams S., Hyslop T., Whellan, D.J., Feldman A.M., Academic Medical Centers and Industry Sponsored Clinical Research Trials, submitted.
204. Marmor, D.B., Feldman, A.M., Whellan, D.J., Rubin, A., Andrei, J., Adams, S., Fiscaro, T., Shamimi-Noori, S., Merli, G.J., Inferior Vena Cava Filter Usage in Post-Surgical Patients: Specialty-Related Disparities, submitted.
205. Hamad, Eman, Mather, P.J., Srinivasan, Siva, Rubin, S., Whellan, D.J., Feldman, A.M., Pharmacologic Therapy of Chronic Heart Failure, *Am J Cardiovasc Drugs*. 2007;7(4):235-48.
206. McTiernan, C.F., Mathier, M.A., Zhu, X., Xiao, X., Klein, E., Swan, C., Mehdi, H., Gibson, G., Glorioso, J.D., Feldman, A.M., McCurry, K., London, B., Myocarditis Following Adeno-Associated Viral Gene Expression of Human Soluble TNF Receptor in Baboon Hearts, *Gene Ther* 2007 Dec; 14(23:1613-22).
207. Funakoshi, H., Lee, L.L., Good, J.C., Hermann, D.E., Koch, W.J., Cheung J., Chan. T.O., Feldman, A.M. Over-expression of the A_{2A}-adenosine receptor rescues the cardiomyopathic phenotype resulting from A₁-adenosine receptor over-expression by normalizing sarcoplasmic reticular Ca²⁺-homeostasis. *CTS, in press*

Books

1. Heart Failure: Pharmacological Management, Feldman, A.M., ed. Blackwell Publishing, 2005
2. Device Therapy in Heart Failure, Feldman, A.M., ed. Blackwell Publishing, in preparation.

Reviews, Chapters, Editorials and Other Publications

1. Feldman, A.M., Epstein, N.H., Brusilow, S.W. Role of cyclic AMP in cerebrospinal fluid production. In *Neurobiology of Cerebrospinal Fluid*. Ed. J. H. Wood, Plenum, New York, pp. 17-27, 1980.
2. Feldman, A.M. Cochlear Biochemistry. In the *Pharmacology of Hearing: Experimental and Clinical Basis*. ed. R. Don Brown and E. A. Diagneault. Wiley and Sons, Inc., New York, pp. 51-80, 1981.
3. Feldman, A.M. Cochlear fluids; Physiology, Biochemistry and Pharmacology. In the *Pharmacology of Hearing: Experimental and Clinical Basis*. Ed. R. Don Brown and E. A. Diagneault. Wiley and Sons, Inc., New York, pp. 81-97, 1981.
4. Baughman, K.L., Feldman, A.M. Dilated Cardiomyopathy. In *Current Therapy in Cardiac Disease 1985-1986*. Ed. N. J. Fortunin, B. C. Decker, Inc., Philadelphia, 1986.
5. Baughman, K.L., Feldman, A.M. Dilated Cardiomyopathy. In *Current Therapy in Internal Medicine*. ed. T.M. Bayless, M.C. Brain and R.M. Cherniack, B.C. Decker, Inc., Philadelphia, pp. 936-945, 1986.

6. Kessler, P.A., Van Dop, C., Feldman, A.M. G-Proteins: Transmembrane signal processors in the heart. *Heart Failure*, 3:239-247, 1988.
7. Feldman, A.M. Biochemical basis for the use of inotropic agents. (Guest editor), *Heart Failure*, 3:223-229, 1988.
8. Feldman, A.M. The Receptor - G protein - adenylate cyclase complex in heart failure. In *Cardiology Update*, E. Rapaport, ed. Elsevier Publishing Co., pp. 213-233, 1990.
9. Feldman, A.M., Bristow, M.R. Adrenergic Neuroeffector Mechanisms in the Failing Human Heart. *Heart Disease-Update*, E. Braunwald, ed. W.B. Saunders Co., New York, pp. 206-216, 1990.
10. Feldman, A.M. Inotropic agents and adrenergic agonists in the treatment of congestive heart failure. *Current Opinions in Cardiology*, 6:363-367, 1991.
11. Bristow, M.R., Feldman, A.M. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. *Basic Res Cardiol*, 87(suppl 1):15-35, 1992.
12. Feldman, A.M. Application of gene amplification by polymerase chain reaction to evaluation of the endomyocardial biopsy. *Heart Failure*, 7:237-244, 1992.
13. Feldman, A.M. Alterations of the β -adrenergic signaling pathway in cardiac failure and its role in pathophysiology and treatment. *Current Opinions in Cardiology*, 7:367-373, 1992.
14. Feldman, A.M. New techniques for the evaluation of the structure, function, and cellular biology of the failing human heart. *Heart Failure*, 7:211-212, 1992.
15. Feldman, A.M., Baughman, K.L., Strobeck, J.E. Oral milrinone in severe chronic heart failure. *N Engl J Med*, 326:1565-1566, 1992 (letter).
16. Rosenblum, W.D., Feldman, A.M. The Cardiac β -Adrenergic transmembrane signaling system. in: Gwathmey, J., Allen, P.D. eds. *Inotropic Drugs: Basic Research And Clinical Practice*, Marcel Dekker, Inc. 9:183-209, 1993.
17. Feldman, A.M. Inotropic agents: The good and the bad. *ACCEL*, 25:7, 1993.
18. Bristow, M.R., Movsesian, M., Feldman, A.M. β -Adrenergic receptor dysfunction in the pathogenesis of idiopathic dilated cardiomyopathy. in Figulla et al (Eds.) *Idiopathic Dilated Cardiomyopathy*, Springer-Verlag, Berlin, pp. 210-221, 1993.
19. Feldman, A.M., Strobeck, J.E. Clinical and Pre-clinical experience with the new positive inotropic agent Vesnarinone, *Heart Failure*, 9(4):156-164, 1993.
20. Feldman, A.M., Bristow, M.R., Parmley, W.W. Effect of Vesnarinone on morbidity and mortality in patients with heart failure. *N Engl J Med*, (letter), 329 (3):149-155, 1993.
21. Feldman, A.M., Strobeck, J.E. Quinolinone derivatives in the management of congestive heart failure. *Coron Artery Dis*, 1994 Feb, 5(2):107-112.

22. Williams, R.E., Feldman, A.M. Inotropic Agents. in: Singh, B.N. ed. Cardiovascular Pharmacology and Therapeutics, Churchill Livingstone, Inc., New York, 21:325-342, 1994.
23. Williams, R.E., Feldman, A.M. New therapeutic agents for the management of congestive heart failure. *Current Opinions in Cardiology*, 9:301-3041, 1994.
24. Feldman, A.M. Edwards, V.T., Lawrence, J.E., Williams, R.E., Rosenblum, W.D., Regulation of gene expression in the failing myocardium: Evidence for a heart failure gene program in Diastolic Relaxation of the Heart, eds Grossman, W., Lorell, B.H., 2:7-16, 1994.
25. Feldman, A.M. The molecular biology of cardiac failure, in Molecular Cell Biology of Cardiovascular Diseases, eds. Diez, J., Dzau, V.J., Ferrari, R., Frolich, E.D. Mosby/Doyma Libros, Inc. pp. 220-237, 1995.
26. Feldman, A.M. Positive Inotropic Therapy for Congestive Heart Failure, in Heart Failure: Scientific Principles and Clinical Practice. Ed., Massie BM. Churchill Livingstone, pp. 701-718, 1996.
27. Reis, S.E., Feldman, A.H., Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. *N Engl J Med* 1997 May 15, 336(20), 1453, author reply.
28. Sasayama, S., Cohn, J.N., Matsuzaki, M., Feldman, A.M. Round Table Discussion: Direction of Heart Failure Research toward the 21st Century. *The Circulation Frontier*, pp. 9-26, 1997.
29. Feldman, A.M. Medical Management of CHF Patients, in Cardiac Transplantation in Perspective. Ed. Loh, E. Marcell Decker, Inc. In Press.
30. Feldman, A.M., Kubota, T., Li, Y.Y., Wagner, D., Combes, A., McTiernan, C.F. New Insights into Dilated Cardiomyopathy: Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart. *Cardiol Clin*, 1998 Nov, 16(4):677-689
31. Alvarez, R.J., Feldman, A.M. Positive inotropic agents in the treatment of heart failure. In: Management of End Stage Heart Disease, *Lippincott Raven*, 53-71, 1998
32. Gorcsan, J., Feldman, A.M., Kormos, R.L., Mandarino, W.A., Demetris, A.J., Batista, R.J.A., *Letter to the Editor*. Effects of partial left ventriculectomy on cardiac performance. *Circulation*, 19:2098, 1998.
33. Feldman, A.M. The Heart Failure Society of America: Looking Towards the Next Millennium. *Congestive Heart Failure*, 6:62, 1998.
34. Soran, O., Schneider, V. M., and Feldman, A.M. Can an anticytokine effectively fight congestive heart failure? *Cardiology Review*, 15(12):53-54, 1998.
35. Soran, O., Schneider, V.M., Feldman, A.M. Current Basic Therapy for Congestive Heart Failure: Current Practice, New Prospects. *Journal of Critical Illness*, 14(2):78-79, 1999.
36. Feldman, A.M., McTiernan, C.F. New insight into the role of enhanced adrenergic receptor-effector coupling in the heart. *Circulation*, 100:579-582, 1999.

37. Feldman, A.M. New targets for treatment of chronic heart failure. *ACCEL*, 31(5), 1999.
38. Feldman, A.M. Heart Failure Awareness. *J of Cardiac Fail*, 5(4):287-9, 1999.
39. Feldman, A.M., Schneider, V.M. Congestive Heart Failure. *Conn's Current Therapy*, pp. 291, 2000.
40. Feldman, A.M. Improving Heart Failure Awareness. *Congestive Heart Failure*, 6:42-3, 2000.
41. Feldman, A.M. Introduction. *Am Heart J*, 139(2):Part 3:S561-2, 2000.
42. Feldman, A.M. Guest Editor: Introduction - The Role of Energy Metabolism Defects in Cardiomyopathy: From Inborn Errors to Ischemia. *Am Heart Journal*, 139(2):Part 3: S561 – S562, 2000.
43. Feldman, A.M. Guest Editor: From clinical trials to clinical practice: What we know and do not know about beta-blockers and the heart. *J of Cardiac Failure*, 6(2): 34-9; 2000.
44. Article Consultant: A step-by-step guide to the best heart failure care. *Patient Care*, 34(11):154-170, 2000.
45. Collins-Nakai, R.L., Dreifus, L.S., Klocke, F.J., Lewis, R.P., Forum Co-Chairs. The ACC Forum on the Future: Delivering Quality Care in the 21st Century. *J Am Coll Cardiol*, 35(5):55B-59B, 2000.
46. Feldman, A.M. Regulating cardiac cytokine expression: The role of the adrenergic nervous system. *Crit Care Med*, 28(11):3754-5, 2000.
47. McTiernan, C.F., Feldman, A.M. The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. *Curr Cardiol Rep*, 2:189-97, 2001.
48. Feldman, A.M. Expert comments: "Improved survival of patients treated with Herceptin and Chemotherapy is offset by Risk of heart Failure" BreastLink, Vol 2: July 2001 Issue.
49. Feldman, A.M., Forward: in Moser, D.K., Riegel, B. eds. An Interdisciplinary Approach to Improving Outcomes in Heart Failure. 2001
50. Leier, C.V., Jessup, M., Giles, T.D., Johnstone, D.E., Ventura, H.O., Dec, W.G., Levine, T.B., Eichhorn, E.J., Feldman, A.M., Bristow, M.R., Pina, I., Binkley, P.F. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 3 – Diagnostic Studies: Laboratory Testing. *Congestive Heart Failure*, 8:49-53, January-February 2002,
51. Feldman, A.M. Adenylyl cyclase: A new target for heart failure therapeutics. *Circulation*, 105:1876-1878. 2002
52. Feldman, A.M., Kadokami, T., Higuichi, Y., Ramani, R., McTiernan, C.F. The role of anticytokine therapy in heart failure: recent lessons from pre-clinical and clinical trials. *Med Clin N Am*, 87: 419-440, 2003.

53. Feldman, A.M., Giles, T.D., Pina, I.L., Talbert, R.L. Clinical trials of beta blockers for heart failure: Questions and controversies. *Cardiology Review*, Nov 2003.
54. McTiernan, C.F., Kadokomi, T., Li, Y.Y., Feldman, A.M. "Experimental heart failure models of cytokine overexpression" In: *The Role of Inflammatory Mediators in the Failing Heart*. ed Douglas Mann, M.D., Kluwer Academic Publishers pg 59-68.
55. Feldman, A.M. "Heart failure as a national health problem" In: *Heart Failure: Providing Optimal Care*. Jessup, M. Editor. Futura Media Services/AHA. 2004.
56. Bristow, M.R., Adams, K.F. Jr., Bauman, J.L., Feldman, A.M., Giles, T.D., Goldstein, S., Mann, D.L., Talbert, R.L. Roundtable Discussion: The COMET Trial, *Congest Heart Fail*, 2005 Jan-Feb: 11(1):39-47.
57. Taneja, T., Gheorghide, M., Feldman, A.M. Intravenous inotropic therapy in patients with advanced heart failure – current understanding and potential future applications. In press.
58. McNamara, D.M., Feldman, A.M. "Heart failure as a consequence of peripartum cardiomyopathy" In: *Heart Failure: A Companion to Braunwald's Heart Disease*. Harcourt Health Sciences, Published 2003 Oct.
59. Feldman, A.M., McNamara, D. Re-evaluating the Role of Phosphodiesterase Inhibitors in the Treatment of Cardiovascular Disease. In press.
60. Feldman, A.M., McTiernan, C., Failing to Mend a Broken Heart But Still Hope for Tumor Necrosis Factor- α Antagonists, *Pharmaceutical & Diagnostic Innovation Newsletter*, Vol 2, Number 3, 1 June 2004; 8-12 (5).
61. Feldman, A.M., Barrington, W. The role of biventricular pacing in the management of heart failure. Submitted.
62. Giles, T.D., Bristow, M., Chatterjee, K., Chien, K., Cohn, J.N., Colluci, W., Feldman, A.M., Ferrans, V., Packer, M., Roberts, R. Report of the 2001 Heart Failure Society of America Task Force on the Definition and Classification of Cardiomyopathies. *J Card Fail*, Submitted.
63. Feldman, A.M. New options in heart failure management: Integration of device therapy. (Editor), National Faculty Meeting, Washington, DC, November 2, 2002. _CD ROM
64. Hunt, S.A., Abraham, W.T., Chin, M., Feldman, A.M., Francis, G.S. Ganiats, T.G., Jessup, M., Konstam, M., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., ACC/AHA Pocket Guideline – Diagnosis and Management of Chronic Heart Failure in the Adult, August 2005
65. Hunt, S.A., Abraham, W.T., Chin, M., Feldman, A.M., Francis, G.A., Ganiats, T.G., Jessup, M., Konstam, M., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., AAA/AHA 2006 Pharmacotherapy Primer for the Diagnosis and Management of Chronic Heart Failure in the Adult, December, 2005
66. Pepine CJ, Feldman A.M. Introduction: there is an important need for increased understanding of the pathophysiology of heart failure postinfarction, new treatment strategies, earlier implementation of effective strategies, and more effective use of existing therapies. *Am J Cardiol* 2006; 97 (10A): 1F-3F. Epub 2006 Apr t.

67. Soran, O., Feldman, A.M., Inotropic Agents, *Congestive Heart Failure*, 3rd Edition, Lippincott, Williams & Wilkins, 2006
68. Feldman, A.M., Review: Molecular Mechanisms of Cardiac Hypertrophy and Failure, Walsh, R.A., ed. Informa Healthcare/Taylor & Francis, 2005, *NEJM*, 355(26), December 28, 2006, 2795-2796.
69. Feldman, A.M., Ho, R.T., Pavri, B., Use of Devices with both Cardiac Resynchronisation And Cardioverter-defibrillator Capabilities, *Cardiac Resynchronization Therapy*, eds. St. John Sutton, M., Bax, J.J., Jessup, M., Brugada, J., Shnalij, M.J., Informa UK Ltd., pp. 261-268, 2007.
70. Yancy, C.W., Feldman, A.M., Race-based therapy, not ready for prime time, submitted.

Selected Abstracts

1. Feldman, A.M., Brusilow, S.W. The effects of cholera toxin on cochlear endolymph. *Fed Proc*, 35:622, 1976.
2. Feldman, A.M., Brusilow, S.W. Hydrostatic fluid pressure in the cochlear compartments. *Fed Proc*, 36:378, 1977.
3. Feldman, A.M., Maylack, F., Epstein, M., Brusilow, S.W. In-vitro effects of prostaglandins on rat choroid plexus. *Clin Res*, 25:430A, 1977.
4. Epstein, M.H., Feldman, A.M. Brusilow S.W. Cerebrospinal fluid production: A possible cyclic AMP mediated secretion. *Neurosurgery*, 2:162-163, 1978.
5. Feldman, A.M., Guilarte, T.R., Baughman, K.L., Gerstenblith, G. Diminished cardiac function in pyridoxine deficiency. *Clin Res*, 33:184A, 1985.
6. Feldman A.M., DeMent, S.H. Waber, L.J., Olson, J.L., Smith R.R.L., Baughman, K.L. The significance of serum carnitine in patients with dilated cardiomyopathies. *Clin Res*, 33:184A, 1985.
7. DeMent, S.H., Feldman, A.M., Olson, J.L., Smith, R.R.L., Baughman, K.L.

Cardiomyopathies: A prospective clinical pathologic study of twenty patients. *Lab Invest*, 52:19A, 1985.
8. Feldman, A.M., Baughman, K.L, Van Dop, C., Levine M.A. Modulation of cardiac adenylate cyclase by ethanol. *Clin Res*, 34:297A, 1986.
9. Feldman, A.M. Kaufman, D.K., Levine, M.A., Gerstenblith, G., Baughman K.L. Negative inotropic effect of furosemide. *Clin Res*, 34:297A, 1986.

10. Midei, M.G., Feldman, A.M., DeMent, S.H., Hutchins, G.M., Baughman, K.L. Myocarditis in peripartum cardiomyopathy. *Clin Res*, 34:326A, 1986.
11. Feldman, A.M., Van Dop, C., Levine, M.A., Baughman, K.L. NAD dependent modulation of cardiac adenylate cyclase. *Circulation*, 74:II-199, 1986.
12. Feldman, A.M., Becker, L.C., Llewellyn M.P., Weisfeldt, M.L., Baughman, K.L. Long-term use of OPC-8212 in patients with congestive heart failure. *Automedica*, 9:60, 1987.
13. Feldman, A.M., Cates, A.E., Baumgartner, W., Baughman, K.L, Van Dop, C. Alterations of the Mr 40,000 pertussis toxin substrate (α Gi) in heart failure. *Circulation*, 76:IV-432, 1987.
14. Midei, M.G., DeMent, S.H., Feldman, A.M., Hutchins, G.M., Baughman, K.L. Peripartum myocarditis and cardiomyopathy. *Circulation*, 76:IV-460, 1987.
15. Kessler, P.D., Cates, A.E., Veazey, W.B., Feldman, A.M. Alterations in receptor-adenylate cyclase coupling in the cardiomyopathic syrian hamster. *J Mol Cell Cardiol*, 20:19, 1988.
16. Feldman, A.M., Cates A.E., Bristow, M.R., Van Dop, C., Expression of the α G gene in heart failure. *J Mol Cell Cardiol*, 20:17, 1988.
17. Kessler, P.D., Cates, A.E., Van Dop C., Feldman, A.M. Altered G protein function in the cardiomyopathic Syrian hamster. *Circulation*, 78:II-560, 1988.
18. Newman, K.D., Michael J.R., Feldman A.M. Inhibition of bovine pulmonary artery adenylate cyclase by phorbol esters is mediated by a pertussis toxin substrate. *Circulation*, 78:II-184, 1988.
19. Tomaselit, G.F., Yellen, G.I., Feldman, A.M., Marban E., Voltage-dependent sodium channels from human cardiac mRNA expressed in xenopus oocytes. *Circulation*, 78:II-26,1998.
20. Hershberger, R.E., Feldman, A.M., Anderson F.L, Kimball, J.A., Wynn, J.R., Bristow, M.R. A Mr 40,000 pertussis toxin substrate (G-protein) is increased in denervated dog heart. *Clin Res*, 37:518A, 1989.
21. Feldman, A.M., Baughman, D.L., Lee, K.L. Van Anden, E., Gottlieb, S., Strobeck, J.E. Randomized double-blind placebo trial of OPC-8212 in patients with heart failure: Morbidity/mortality in 80 patients. *Circulation*, 80:II-176, 1989.
22. Feldman, A.M., Jackson, D.G., Bristow, M.R., Van Dop, C. Immunologic quantification of G proteins in failing and non-failing human heart. *Circulation*, 80:II-293, 1989.
23. Kessler, P.D., Tena, R.G., Weisman, H.F., Van Dop, C., Feldman, A.M. Ventricular dilatation is associated with functional abnormalities of the G stimulatory protein in BIO 53.58 Syrian hamsters. *Circulation*, 80:II-293, 1989.
24. Baughman, K.L, Herskowitz, A., Feldman, A.M., Hutchins, G.M. Peripartum cardiomyopathy with myocarditis: Who to treat. *Circulation*, 80:II-320, 1989.
25. Bristow, M.R., Skerl, L., Jackson D.G., Larrabee, P., Feldman, A.M. Uncoupling of β -

- adrenergic receptors and increased αG_i in Ischemic Dilated Cardiomyopathy. *Circulation*, 82:II-567, 1990.
26. Bristow, M.R., Durham, C., Kline, J., Rasmussen R., Port, J.D., Gesteland, R.R., Barry, W.H., Feldman, A.M. Down-regulation of β -adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. *Clin Res*, 39:256A, 1991.
 27. Feldman, A.M., Ray, P.E. Johns, D.C., Han, R. Molecular regulation of signal transduction proteins in heart failure. *J Mol Cell Cardiol*, 23(S III), 1991.
 28. Feldman, A.M., Ray, P.E. G protein gene expression in human heart by quantitative polymerase chain reaction. *Circulation*, 84:II-571, 1991.
 29. Feldman, A.M. Ray, P.E., Sherman, S.I., Baughman, K.L, Ladenson, P.W. Reversible alterations in cardiac gene expression in a patient with dilated cardiomyopathy and hypothyroidism: serial measures by quantitative polymerase chain reaction. *J Am Coll Cardiol*, 19:272A, 1992.
 30. Feldman, A.M., Bristow, M.R., Parmley, W.W., Carson , P.E., Pepine C.J., Gilbert, E.M., Strobeck J.E., Hendrix, G.H., Powers, E.R., Bain, R.P., White, B.G., for the OPC-8212 Investigators and Coordinators. Results of a multi-center study of OPC-8212 in chronic congestive heart failure. *Circulation*, 86:I-374, 1993.
 31. Sharir, T., Van Anden, E., Marmor, A., Feldman, A.M., Kass, D.A. Non-invasive assessment of drug induced load vs inotropic change by maximal ventricular power/EDV² in humans. *Circulation*, 86:I-714; 1993.
 32. Bristow, M.R., Minobe, W.A., Port, J.D., Ray, P.E., Feldman, A.M. Decreased β_1 adrenergic receptor mRNA levels in the failing human heart. *J Am Coll Cardiol*, 21:100A; 1993.
 33. Weinberg, E.O., Ray, P.E., Lorell, B.H., Feldman, A.M. Selective changes in gene programming characterize the transition from hypertrophy to failure in aortic banded rats. *J Am Coll Cardiol*, 21:373A; 1993.
 34. Feldman, A.M., Pepine, C.J., Bristow, M.R., Hendrix, G.H., Power, E.R., Bertolet, B., Baughman, K.L, Young, N. Cowart, D., White B.G. Incidence of vesnarinone induced neutropenia: the U.S. experience. *Circulation*, 88(4): I-301, 1993.
 35. Williams, R.E., Sabbah, H.N., Ray, P.E. Goldstein, S., Feldman, A.M., Differential expression of myocardial creatine kinase isoforms in dogs with chronic heart failure. *Circulation*, 88(4):I-283, 1993.
 36. Carson, P.E., Colucci, W.S., Deedwania, P.C., Uretsky, B.F., Bristow, M.R., Feldman, A.M., Cowart D. for vesnarinone investigators. Lack of proarrhythmia or arrhythmia reduction by vesnarinone in advanced heart failure. *Circulation*, 88(4):I-602, 1993.
 37. Haber, H.L., Wu, C.C., Tedesco, C.L., Carnivale, M., Pak, P.H., Feldman, A.M., Bergin J.D., Coward T.D, Powers, E.R., Kass, D.A. Clinical determination of myocardial vs load effects of OPC-18790. A novel intravenous agent for the treatment of patients with congestive heart failure. *Circulation*, 88(4):I-301, 1993.

38. Kass, D.A., Van Anden, E., Kiernan-Pownall, K., Carnivale, K., White, W.G., Feldman, A.M., Positive inotropic activity of vesnarinone in patients with dilated cardiomyopathy. *Circulation*, 90(4):1-111, 1994.
39. Bristow, M.R., Minobe, W.A., Reynolds, M.V., Roden R.L., Port J.D., Feldman, A.M. Age related decreases in β_1 receptor mRNA abundance in human heart. *J Am Coll Cardiol*, 17A, February 1994.
40. Lowes B.D., Abraham, W.T., Minobe, W., Feldman, A.M., Bristow, M.R. Assessment of gene expression in endomyocardial biopsy specimens from failing and nonfailing human hearts. *J Invest Med*, 43 (suppl 2):316A, 1995.
41. Winobe, W., Lowes, B.D., Abraham, W.T., Feldman, A.M. Bristow, M.R. In Vivo measurement of myocardial gene expression in the human heart. *J Am Coll Card*, 277A, 1995.
42. McGowan, G.A., Mann, D.L. Kormos, R.L. Feldman, A.M. Muralis, S. Clinical correlates of circulating interleukin-6 in severe heart failure. *Circulation*, 94(8):1-329, 1996.
43. Reis, S.E., Holubkov, R., McNamara, D.M., Edmundowicz, D., Zell, K.A., Detre, K.M., Felman, A.M. Therapy of congestive heart failure by cardiologists is a cost-effective method of improving patient outcomes. *Circulation*, 94(8): -194,1996.
44. Li, Y.Y., McTiernan, C.F., Feldman, A.M., Messenger RNA differential display identifies a novel cytokine responsive gene in neonatal rat cardiomyocyte. *Circulation*, 94(8):1-643,
45. Kubota, R., McTiernan, C.F., Frye, C.S., Demetris, A.J., Feldman, A.M. Cardiac specific overexpression of tumor necrosis factor - α causes lethal myocarditis in transgenic mice. *J Am Coll Card*, 29(2):346A, 1997.
46. Feldman A.M., Young J., Bourge R., Carson P., Jaski B., DeMets, D. White B.G. Cohn, J.N. Mechanism of Increased Mortality From Vesnarinone in the Severe Heart Failure Trial (VEST). *J Am Coll Card*, 29(2):64A, 1997.
47. Gorcsan, J., Dishart M., Mandarino, W.A., Feldman, A.M., Pinsky, M.R. Toborinone attenuates myocardial depression in sepsis. *Circulation*, 96(8):1-391, 1997.
48. Olds, N.B., Varvaro, F.F., Janosko, K., Trost, M., Zullo, T.G., Feldman, A.M., Murali, S. Gender differences in assessment of quality of life in patients with heart failure. *Circulation*, 96(8):1-440, 1997.
49. Li, Y.Y., Feldman, A.M., McNamara, D.M., Rosenblum, W.D., McTiernan, C.F. Differential gene expression of tissue inhibitors of metalloproteinases in congestive heart failure. *Circulation*, 96(8):1-520,1997.
50. Katz, W.I., Gulati, V., Feldman, A.M., Crawford, L., Peron, M., Soran, O., Gorcsan, J. Effects of enhanced external counterpulsation on internal mammary artery flow: comparison with intraaortic balloon counterpulsation. *J Am Coll Card*, 31:85A, 1998.
51. Bozkurt, B., Alvarez, R.J., McNamara, D.M., MacGowan, G.A., Rosenblum, W.D.,

- Feldman, A.M., Murali, S. Explant myocarditis: Evidence for the role of inflammation in decompensation of advanced heart failure patients. *J Am Coll Card*, 31(2), 330A, 1998.
52. Cohen, H.A., Zenati, M., Griffith, B., Smith, A.J.C., Lee, J.S., Chough, S., Izzo, M., Jafar, Z., Feldman, A.M., Counihan, P.J., Feldman, A.M. Integrated coronary revascularization-minimally invasive coronary bypass combined with angioplasty: initial experience in 25 patients. *J Am Coll Card*, 31(2):70A, 1998.
 53. Bozkurt, B., Alvarez, R.J., Rosenblum, W.D., MacGowan, G.A., Feldman, A.M., Murali, S., McNamara, D.M. Role of immune globulin in the treatment of postpartum cardiomyopathy. *J Am Coll Card*, 31(2):330A, 1998.
 54. McNamara, D.M., Trost, M.K., Palmer, A.D., Rudy, M., Alvarez, R.J., Rosenblum, W.D., MacGowan, G.A., Murali, S., Feldman, A.M. Angiotensin converting enzyme deletion polymorphism does not increase the risk of heart failure. *J Am Coll Card*, 31(2):156A, 1998.
 55. Gorcsan, J., Feldman, A.M., Mandarino, W.A., Kormos, R.L., Batista, R.J.V. Heterogeneous immediate effects of partial left ventriculectomy on cardiac performance. *J Am Coll Card*, 31(2):225A, 1998.
 56. Wagner, D.R., Combes, A., McTiernan, Feldman, A.M. Adenosine Inhibits immediate cardiodepressive effects of tumor necrosis factor-alpha in adult cardiomyocytes. *J Am Coll Card*, 31(2):288A, 1998.
 57. Wagner, D.R., McTiernan, C., Feldman, A.M. Adenosine inhibits cardiac expression of tumor necrosis factor-alpha in the failing human heart. *J Am Coll Card*, 31(2):203A, 1998.
 58. Bozkurt, B., Alvarez, R.J., McNamara, D.M., MacGowan, G.A., Rosenblum, W.D., Feldman, A.M., Murali, S., Explant Myocarditis: Evidence for the role of inflammation in decompensation of advanced heart failure patients. *J Am Coll Card*, 31(2):330A, 1998.
 59. Wagner, D.R., McTiernan, C.F., Feldman, A.M. Differential Effects of Exogenous and Endogenous Adenosine on Myocardial Proinflammatory Cytokine Gene Expression. *J of Cardiac Failure*, 4(3):17, 1998.
 60. McTiernan, C.F., Frye, C., Lemster, B., Kinder, E.A., Moravec, C., Feldman, A.M. The Human Phospholamban Gene: Expression and Structure. *J of Cardiac Failure*, 4(3):23, 1998.
 61. Kubota T, Miyagishima M, Bounoutas GS, McTiernan CF, Feldman AM. Overexpression of tumor necrosis factor- α activates the expression of multiple members of the apoptosis pathway in transgenic mice. *J of Cardiac Failure*, 4(3):23, 1998.
 62. Bounoutas GS, Kubota T, Miyagishima M, McTiernan CF, Bruton C, Robbins PD, Feldman, AM. Adenoviral directed overexpression of soluble tumor necrosis factor receptors reverses myocarditis in transgenic mice with congestive heart failure. *J of Cardiac Failure*, 4(3):23, 1998.
 63. Li, YY, McTiernan, CF, Feldman, AM. Upregulation and persistent activation of c-Jun-NH₂-terminal kinases in the ischemic failing human heart. *J of Cardiac Failure*, 4(3):23, 1998.

64. Gorcsan J, Murali S, Mandarino WA, Feldman AM. Positive Inotropic effects of vesnarinone in severe heart failure: Results of the VEST Ventricular Function substudy. *J of Cardiac Failure*, 4(3):48, 1998.
65. Bolinger, Seybert, A., Alvarez, R.A., MacGowan, G.A., McNamara, D.M., Rosenblum, W.D., Feldman, A.M., Murali, S. Optimal Intravenous Inotropic Therapy in Severe Congestive Heart Failure. *J of Cardiac Failure*, 4(3):60, 1998.
66. Gorcsan, J., Mankad, S., Mandarino, W.A., Feldman, A.M. Murali, S. Quantification of regional diastolic function in patients with severe heart failure by tissue doppler time velocity gradients. *J Am Soc Echocardiogr*, 11:519, 1998.
67. Gorcsan J, Murali S, Mandarino WA, Feldman AM. Inotropic effects of vesnarinone in severe heart failure; results of the VEST ventricular function substudy. *Circulation*, 98(17):I-579, 1998.
68. Pan X, Baker L, Lee JS, Kubota T., Feldman AM, Salama G, London B. Atrial and ventricular arrhythmias in transgenic mice with myocardial expression of TNF- α . *Circulation*, 98(17):I-745, 1998.
69. Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM. Postmenopausal estrogen use predicts improved survival in women with congestive heart failure. *Circulation*, 98(17):I-205, 1998.
70. Kubota T, Bounoutas GS, Miyagishima M, McTiernan CF, Feldman AM. Development of myocarditis in transgenic mice overexpressing tumor necrosis factor - α is mediated in part by the selective induction of downstream proinflammatory cytokines and β -chemokines. *Circulation*, 98(17):I-345, 1998.
71. Kubota T, Miyagishima M, Bounoutas GS, McTiernan CF, Feldman AM. Overexpression of tumor necrosis factor- α activates the expression of multiple members of the apoptosis pathway in transgenic mice. *Circulation*, 98(17):I-462, 1998.
72. Bounoutas GS, Kubota T, Miyagishima M, McTiernan CF, Bruton C, Robbins PD, Feldman, AM. Adenoviral directed overexpression of soluble tumor necrosis factor receptors reverses myocarditis in transgenic mice with congestive heart failure. *Circulation*, 98(17):I-737, 1998.
73. Gottipaty, VK, Krelis, SP, Spencer, EP, White, BG, Shusterman, V, Weiss, R, Brode, S, White, A, Schwartzman, D, Anderson, KP, Feldman, A.M., for the VEST Investigators. QRS dispersion, unlike QT dispersion, is a predictor of all cause mortality in patients with symptomatic congestive heart failure. *PACE* , 22:765, 1999.
74. Gottipaty, VK, Krelis, SP, Spencer, EP, White, BG, Shusterman, V, Weiss, R, Brode, S, White, A, Schwartzman, D, Anderson, KP, Feldman, A.M., for the VEST Investigators. Paroxysmal atrial fibrillation predicts increased mortality in patients with symptomatic congestive heart failure and cardiomyopathy. *PACE*, 22:450-812, 1999.
75. Gottipaty, V.K., Krelis, S.P, Lu, F., Spencer, E.P., Shustermen, V., Weiss, R., Brode, S., White, A., Anderson, K.P., White, B.G., Feldman, A.M., for the VEST Investigators. The

- resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. *J Am Coll Card*, 33(2):145A1, 1999.
76. Bozkurt, B., Torre-Amione, G., Soran, O.Z., Feldman, A.M., Blosch, C., Warren, M. Mann, D.L. Results of a multidose Phase I trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure. *J Am Coll Card*, 33(2):184A, 1999.
 77. McNamara, D.M., Holubkov, R., Janosko, K., Palmer, A., Wang, J.J., Trost, M., Alvarez, R.J., Jr., Rosenblum, W.D., MacGowan, G.A., Murali, S., Feldman, A.M. Angiotensin converting enzyme genotype predicts prognosis in patients with congestive heart failure. *J Am Coll Card*, 33(2):189A, 1999.
 78. Soran, O.Z., Young, J., White, B.G., Feldman, A.M. Withdrawal of the inotropic agent vesnarinone is not associated with an adverse outcome: substudy results from the VEST Trial. *J Am Coll Card*, 33(2):200A, 1999.
 79. Murali, S., Bollinger, K., Trost, M., Tokarczyk, T., Palmer, A., Alvarez, R.J., Jr., MacGowan, G.A., McNamara, D.M., Rosenblum, W.D., Feldman, A.M. Is continuous intravenous prostacyclin infusion effective in secondary pulmonary hypertension. *J Am Coll Card*, 33(2):270A, 1999.
 80. Murali, S., Bollinger, K., Tokarczyk, T. Trost, M., Palmer, A., Alvarez, R.J., Jr., MacGowan, G.A., McNamara, D.M., Rosenblum, W.D., Feldman, A.M. Hemodynamic, functional, echocardiographic and survival benefits of long-term continuous intravenous prostacyclin infusions in primary pulmonary hypertension. *J Am Coll Card*, 33(2):308A, 1999.
 81. Soran, O.Z., DeMarco, T., Crawford, L.E., Schneider, V.M., de Lame, P.A., Grossman, W., Feldman, A.M. Efficacy and safety of enhanced external counterpulsation in mild to moderate heart failure: A preliminary report. *J Card Failure*, 5(3):53, 1999.
 82. Strobeck, J.E., Reade, R., Kennard, E.D., Kelsey, S.F., Soran, O., Feldman, A.M. Enhanced external counterpulsation is a safe and effective treatment for angina in patients with severe left ventricular dysfunction. *J Card Failure*, 5(3):72, 1999.
 83. McNamara, D.M., Holubkov, R., Wang, J.J., Janosko, K., Palmer, A., Rosenblum, W.D., MacGowan, G.A., Murali, S., London, B., Feldman, A.M. The Asp²⁹⁸ variant of endothelial nitric oxide synthase (eNOS) improves survival in patients with heart failure. *Circulation*, 100:I-507, 1999.
 84. London, B., Baker, L.C., Kubota, T., Wolski, T.C., Metz, H.A., Choi, B.R., Feldman, A.M., Salama, G. Slow conduction of premature beats leads to ventricular tachycardia in a TNF- α transgenic model of congestive heart failure. *Circulation*, 100:I-207, 1999.
 85. Soran, O.Z., DeMarco, T., Crawford, L.E., Schneider, V., Levy, F., de Lame, Paul-Andre, Gorcsan, J., III, Benedict, C.R., Grossman, W., Feldman, A.M. Safety of enhanced external counterpulsation in heart failure patients. *Circulation*, 100:I-300, 1999.
 86. Li, Y.Y., McTiernan, C.F., Moravec, C.S., Kormos, R.L., Feldman, A.M. The activated matrix metalloproteinase-9 in the failing human heart is suppressed by LVAD support. *Circulation*, 100:I-560, 1999.

87. Li, Y.Y., Mi, Z., McTiernan, C.F., Robbins, P.D., Feldman, A.M. Two forms of ephrin-A5 differentially regulate gene expression in neonatal rat cardiomyocytes. *Circulation*, 100:I-42, 1999.
88. Li, Y.Y., Feng, Y.Q., Kadokami, T., McTiernan, C.F., Feldman, A.M. Modulation of matrix metalloproteinase activities remodels myocardial extracellular matrix in TNF α transgenic mice. *Circulation*, 100:I-752, 1999.
89. Kadokami, T., Kubota, T., Bounoutas, G.S., McTiernan, C.F., Feldman, A.M. Soluble tumor necrosis factor receptor differentially regulates cardiac cytokine gene expression in mice with lipopolysaccharide-induced endotoxemia. *Circulation*, 100:I-16, 1999.
90. Kadokami, T., McTiernan, C.F., Kubota, T., Feldman, A.M. Gender-specific differences in survival in murine dilated cardiomyopathy is attributed to differences in cytokine receptor expression. *Circulation*, 100:I 276, 1999.
91. McNamara, D.M., Starling, R.C., Dec, G.W., Loh, E., Torre-Amione, G., Gass, A., Janosko, K.M., Tokarczyk, T., Holubkov, R., Feldman, A.M. Intervention in myocarditis and acute cardiomyopathy with immune globulin: results from the randomized placebo controlled IMAC trial. *Circulation*, 100:I-21, 1999.
92. Gorcsan, J., III, Crawford, L.E., Soran, O., Wang, H., Severyn, D., de Lame, Paul-Andre, Schneider, V.M., Feldman, A.M. Improvement in Left Ventricular Performance by Enhanced External Counterpulsation in Patients with heart failure. *J Am Coll Card*, 35:230A, 2000.
93. Bozkurt, B., Torre-Amione, G., Soran, O.Z., Feldman, A.M., Whitmore, J., Warren, M., Mann, D.L. Safety and efficacy of ENBREL (Etanercept) in the treatment of chronic heart failure. *J Am Coll Card*, 35:240A, 2000.
94. Gorcsan, J., III, Feldman, A.M., Hao, W., Severyn, D., Moore, G.E., Feldman, A.M., Detection of progressive alterations in regional myocardial function by tissue doppler velocity gradient in a rapid pacing model of heart failure. *J Am Coll Card*, 35:448A, 2000.
95. Soran, O.Z., Kennard, E.D., Holubkov, R., Strobeck, J.E., Feldman, A.M. Six-month outcome of patients with left ventricular dysfunction treated with enhanced external counterpulsation (EECP) for chronic angina. *E Heart J*, 21:3261, 2000.
96. Ramani, R.N., Tokarczyk, T.R., Janosko, K., Palmer, A.D., Wang, J.J., Rosenblum, W.D., MacGowan, G.A., Murali, S., London, B., Feldman, A.M., Holubkov, R., McNamara, D.M.,. The effect of the Asp²⁹⁸ variant of endothelial nitric oxide synthase (eNOS) on functional capacity in patients with heart failure. *J Card Failure*, 6:118, 2000.
97. Gorcsan, J., III, Mulukutla, S., Wang, H., Jacques, D., Feldman, A.M. Measurement of left ventricular wall motion asynchrony in patients with left bundle branch block using tissue doppler echocardiography. *J Card Failure*, 6:160, 2000.
98. Soran, O.Z., DeMarco, T., Crawford, L.E., Schneider, V.M., de Lame, P.A., Fleishman, B., Grossman, W., Feldman, A.M. Enhanced external counterpulsation in heart failure patients: results of a pilot study. *J Card Failure*, 6:180, 2000.

99. Janosko, K.M., Tokarczyk, T.R., Palmer, A.D., MacGowan, G.A., Rosenblum, W.D., Murali, S., Holubkov, R., Feldman, A.M., McNamara, D.M. Improved survival with beta-blocker therapy: Is there equality between the sexes? *J Card Failure*, 6:280, 2000.
100. Soran, O.Z., Kennard, E.D., Holubkov, R., Strobeck, J.E., Feldman, A.M. Six month outcome of patients with left ventricular dysfunction treated with enhanced external counterpulsation (EECP). *J Card Failure*, 6:282, 2000.
101. Lawson, W.E., Hui, J.C.K., Kennard, E.D., Holubkov, R., Kelsey, S.F., Strobeck, J.E., Feldman, A.M. Benefit and safety of enhanced external counterpulsation in the treatment of ischemic heart disease with history of congestive heart failure. *J Card Failure*, 6:316, 2000.
102. Kadokami, T., McTiernan, C.F., Kubota, T., Feldman, A.M. Long-term estradiol treatment improves survival in male mice with heart failure induced by cardiac specific TNF- α expression. *Circulation*, 102:II-72, 2000.
103. Li, Y.Y., Kadokami, T. McTiernan, C.F., Feldman, A.M. MMP inhibition prevents myocardial fibrosis and improves myocardial function and survival in a transgenic model of heart failure. *Circulation*, 102:II-132, 2000.
104. McTiernan, C.F., Kadokami, T., Lemster, B.H., Frye, C.S., Wagner, C.L., Feldman, A.M. Anti-TNF α antibody limits progression of heart failure in a murine transgenic model. *Circulation*, 102:II-265, 2000.
105. McNamara, D.M. Holubkov, R., Janosko, K.M., Palmer, A.D., Macgowan, G.A., Rosenblum, W.D., Murali, S., London, B., Feldman, A.M. Pharmacogenetic interaction of the ace deletion polymorphism and beta blocker therapy in heart failure survival. *Circulation*, 102:II-378, 2000.
106. Kubota, T., Alvarez, R.J., Kormos, R.L., Rosenblum, W.D., Semigran, M.J., Dec, G.W., Holubkov, R., McTiernan, C.F., Feldman, A.M., McNamara, D.M. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage cardiomyopathy. *Circulation*, 102:II-414, 2000.
107. Alvarez, R.J., Miyagishima, M., Kubota, T., Rosenblum, W.D., McCurry, K.R., McTiernan, C.F., Griffith, B.P., Feldman, A.M., Kormos, R.L., McNamara, D.M. Elevation of myocardial cytokine expression in end-stage heart failure and effect of LVAD support. *Circulation*, 102:II-501, 2000.
108. Missov, E., Wieczorek, S., Wu, A., Bozkurt, B., Soran, O., Warren, M., Devries, T., Feldman, A.M., Torre-Amione, G., Mann, D.L., DeMarco, T. Brain natriuretic peptide levels are associated with improved clinical status in patients with chronic heart failure after treatment with Enbrel (Etanercept, TNF receptor). *Circulation*, 102:II-532, 2000.
109. Shusterman, V., Usiene, I., Aysin, B., Lee, J.S., Feldman, A.M., London, B. Slow rhythm destabilization precedes initiation of ventricular arrhythmias in a TNF-? Mouse model of congestive heart failure. *NASPE*, 2001.
110. Funakoshi, H., Kubota, T., Kawamura, N., Machida, Y., Feldman, A.M., Takeshita, A. Targeted disruption of inducible nitric oxide synthase does not improve the survival of transgenic mice with cytokine induced cardiomyopathy. *Circulation*, 104:II-196, 2001.

111. Kadokami, T., McTiernan, C.F., Frye, C.S., Feldman, A.M. Acute exacerbation of heart failure during peripartum period in transgenic mice with cardiac-specific TNF- α overexpression. *Circulation*, 104:II-196, 2001.
112. Kawamura, N., Kubota, T., Machida, Y., Funakoshi, H., Ide, T., Feldman, A.M., Tsutsui, H. Overexpression of copper-zinc superoxide dismutase rescues transgenic mice with cytokine-induced dismutase. *Circulation*, 104:II-93, 2001.
113. Li, Y.Y., Wang, P., McTiernan, C.F., Kormos, R.L., Feldman, A.M. Differential expression of tissue inhibitors of metalloproteinases in various regions of the failing human heart. *Circulation*, 104:II-306, 2001.
114. Li, Y.Y., Wang, P., McTiernan, C.F., Pei, W., Moravec, C.S., Kormos, R.L., Feldman, A.M. Reversal of the down-regulation of tissue inhibitors of metalloproteinases and collagen damage in the failing human heart after mechanical support. *Circulation*, 104:II-185, 2001.
115. McNamara, D. M., Holubkov, R., Postava, L.A., Janosko, K.M., Palmer, A.D., MacGowan, G.A., Mathier, M.A., Murali, S., Feldman, A.M., London, B. Pharmacogenetic interaction of the ACE deletion polymorphism and high dose ACE inhibitor therapy in heart failure survival. *Circulation*, 104:II-594, 2001.
116. Postava, L.A., Holubkov, R., Janosko, K.M., Palmer, A.D., MacGowan, G.A., Murali, S., Mathier, M.A., Feldman, A.M., London, B., McNamara, D.M. The aldosterone synthase promoter polymorphism modulates the effect of the ACE D-allele on heart failure survival. *Circulation*, 104:II-2, 2001.
117. Saba, S., McTiernan, C.F., Feldman, A.M., London, B. Cardiac conduction and repolarization abnormalities in a mouse model of dilated cardiomyopathy secondary to cardiac specific TNF- α overexpression. *NASPE*, Submitted
118. McNamara, D.M., Holubkov, R., Postava, L.A., Palmer, A., Janosko, K., MacGowan, G.A., Mathier, M.A., Murali, S., Feldman, A.M., London, B. Polygenic risk assessment improves usefulness of genotyping in heart failure populations: additive effects of ACE and eNOS Polymorphisms. *J Am Coll Cardiol*, 39:134A, 2002.
119. Mahlab, D.S., Postava, L.A., Holubkov, R., Shilkofsky, J., MacGowan, G.A., Mathier, M.A., Murali, S., Janosko, K., Feldman, A.M., London, B., McNamara, D.M. β -2 adrenergic receptor variant Ile164: effect on heart failure survival and impact of beta blockade. *J Am Coll Cardiol*, 39:135A.
120. Sonel, A.F., Shalaby, A., McConnell, J.P., Hogen, S., Feldman, A.M. Detectable troponin T level predicts high mortality in patients with heart failure undergoing internal defibrillator implantation. *J Am Coll Cardiol*, 39:159A.
121. Feldman, A.M., Klein, H., Tchou, P., The WEARIT & BIROAD Investigators. New therapeutic option for patients with time-dependent risk of sudden cardiac arrest: application of novel wearable cardioverter-defibrillator. *J Am Coll Cardiol*, 39:101A, 2002.

122. Soran, O., Michaels, A.D., Kennard, L., Kelsey, S., Feldman, A.M. The Incidence of Repeat Enhanced External Counterpulsation in Patients with Refractory Angina Who are not Candidates for Invasive Revascularization: Results from the International EECF Patient Registry, Submitted.
123. Ramani, R., Wang, P., Mathier, M., McTiernan, C., Feldman, A.M., Inhibition of Tumor Necrosis Factor- α Receptor-1 Mediated Pathways Has Beneficial Effects in a Murine Model of Ischemic Cardiomyopathy. *J Am Coll Cardiol*, 8(4):003, 2002.
124. Soran, O., Kennard, E.D., Feldman, A.M., Do Women with Left Ventricular Dysfunction and Refractory Angina Respond as Well as Men to Enhanced External Counterpulsation. *J Am Coll Cardiol*, 8(4): 291, 2002.
125. Feldman, A.M., Schneider, B.J., How Physicians Grade Heart Failure Diagnosis and Treatment in the U.S.: Perception of a Random Population of U.S. Physicians, *J Am Coll Cardiol*, 8(4): 350, 2002.
126. Janczewski, A.M., Zahid, M., Higuchi, Y., Lemster, B.H., Frye, C.B., Feldman, A.M., McTiernan, C.F. Phospholamban Ablation Improves Calcium Transients but Not Cardiac Function in a Mouse Model of Heart Failure. *Circulation*, 106(19): 1282, 2002.
127. Wang, I., Natalio, A., Litwak, K.N., Wang, Q., McTiernan, C.F., Feldman, A.M., Kormos, R.L. Aldosterone and Myocardial Collagen Changes in Pulsatile and Continuous Flow LVAD-Supported Calves. *Circulation*, 106(19): 2085, 2002.
128. Soran, O., Pina, I., Lamas, G., Huck, K., Roges, O., Schneider, V., Kelsey, S.F., Feldman, A.M. The Heart Failure Home Care (HFHC) Trial: A Multicenter, Randomized, Controlled Trial of a Computer Based Telephone Heart Failure Monitoring System: Design and Methods. *Journal of Cardiac Failure*, 9(5): S113, 2003.
129. DeMarco, T., Boehmer, J.P., Higginbotham, M.B., Krueger, S.K., Lowes, B., Fenster, P.E., Kennett, J.D., Wagoner, L.E., Ghali, J., Kirlin, P., Saxon, L., Feldman, A.M., Birstow, M.R. Cardiac Resynchronization Therapy Improves Functional Status and Quality of Life in Heart Failure: Results from the Comparison of Medical therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Exercise Performance Sub-Study. *Circulation* 2003: Supp IV, 108(17), 628.
130. Carson, P., Anand, I., O'Connor, C.M., Lindenfield, J., Steinberg, J., Ghali, J., Jaski, B., Lwin, A., Feldman, A.M., Bristow, M. Relation of Cardiac Device Therapy to Mode of Death in Advanced Heart Failure – COMPANION Trial. *Circulation* 2003: Supp IV, 108(17) 628.
131. Feldman, AM, Clinical characteristics of vesnarinone. *Drug Saf.*, 2004; 27 Suppl 1:1-9.
132. London, B, Zhu, X, Feldman, AM, Glorioso, JC, Myocarditis in Baboon Hearts Injected with Adeno-Associated Virus Expressing Soluble Tumor Necrosis Factor Receptors, *Circulation Supp*, 110(17) III-161, 2004
133. Higuchi, Y., Chan, T.O., McTiernan, C.F., Kones, W.K., Feldman, A.M., Blockade of NF- κ B activation inhibits hypertrophy and improves survival in Male Mice with Heart Failure

- Induced by Cardiac-Specific TNF- α Expression, *Circulation Supp*, 110(17) III-13, 2004
134. Bristow, M.R., Oren, R., Abraham, W.T., Zisman, L., Shakar, S., Kao, A., Mathier, M., McGrew, F., Gilbert, E.M., Leier, C., Carson, P., Lowes, B.D., Boehmer, J., Krueger, S., Robertson, A.D., Liard, J., Gerber, M., Feldman, A.M., Low-dose oral enoximone reduces i.v. inotrope and use in end stage heart failure patients: The Oral Enoximone in Intravenous Inotrope-dependent Subjects (EMOTE) trial. *European Card. Soc.*, in press, 2004
 135. Higuchi, Y., Chan, T.O., DeGeorge Jr., B., McTiernan, C.F., Feldman, A.M., AKT Activity is Downregulated via TNF Receptor 1 in Transgenic Mice with Cytokine-Induced Cardiomyopathy, Submitted, 2004.
 136. Feldman, A.M., presenter, Oral Enoximone in Intravenous Inotrope-Dependent Subjects (EMOTE), *J of Card Fail*, 2004.
 137. Feldman, A.M., deLissovoy, G., Bristow, M.R., Saxon, L.A., DeMarco, T., Kass, D.A., Boehmer, J., Singh, S., Whellan, D.J., Carson, P., Boscoe, A., Baker, T., Gunderman, M.R., Cost Effectiveness of Cardiac-Resynchronization Therapy With and Without a Defibrillator in COMPANION Heart Failure Patients, *J Amer Coll Card*, Supp A, 2005 45(3), 160A.
 140. Sumner, A.D., Boehmer, J., Saxon, L.A., Feldman, A.M., Bristow, M.R. Statin Use is Associated with a Marked Improvement in Survival in an Advanced Heart Failure Population from the COMPANION Trial, *J Amer Coll Card*, Supp A, 45(3), 183A, 2005.
 141. McNamara, D.M., Tam, S.W., Sabolinski, M.L., Palmer, A., Tobelman, P., Juanosko, K., Feldman, A.M., Worcel, M., The Genetic Risk Assessment Sub-Study of the African-American Heart Failure Trial (A-HeFT): Impact of Genetic Variation of NOS3. *J of Card Fail*, 2005 Aug, 11(6), S152.
 142. Most, P., Gao, E., Funakoshi, H, Voelkers, M., Heierhorst, J., Eckhart, A., Pleger, S.T., Feldman, A.M., Katus, H.A., Koch, W.J., Cardiac S100a1 Protein Levels Determine Left Ventricular Performance Propensity Towards Heart Failure After Myocardial Infarction in Mice, *Circulation Supp*, 112(17), Oct 25, 2005.
 143. Lindenfeld, J., Feldman, A.M., Saxon, L., Boehmer, J., Carson, P., Ghali, J., Steinberg, J., DeMarco, T., Mann, D., Yong, P., Galle, E., Ecklund, F., Bristow, M., Cardiac Resynchronization Therapy with and without Debrillator Improve Time to Death and Hospitalization in NYHA Class IV Heart Failure Patients, *Circulation Supp*, 112(17), Oct 25, 2005.
 144. Bristow, M.R., Saxon, L., DeMarco, T., Boehmer, J., Galle, E., Yong, P., Ecklund, F., Feldman, A.M., What Does an ICD Add to CRT in Advanced Heart Failure Patients? An Analysis of Major Clinical Endpoints in the CRT vs. CRT-D Groups in the COMPANION Trial, *Circulation Supp*, 112(17), Oct 25, 2005.
 145. Bristow, M.R., Saxon, L.A., Boehmer, J., DeMarco, T., Carson, P., Yong, P., Galle, E., Ecklund, F., Feldman, A.M., COMPANION Study Investigators, Baseline Factors That Predict Clinical Response with Cardiac Resynchronization Therapy: The COMPANION

- Experience, *Circulation Supp*, 112(17), Oct 25, 2005.
146. Bristow, M.R., Yong, P., Saxon, L.A., Jaski, B., Boehmer, J., Galle, E., Ecklund, F., Feldman, A.M., COMPANION Study Investigators, Do Multiple Comorbidities Diminish The Ability of CRT to Reduce Mortality and Hospitalization? *Circulation Supp*, 112(17), Oct 25, 2005.
 147. McNamara, D.M., Tam, S.W., Sabolinski, M.L., Tobelman, P., Palmer, A., Janosko, K., Feldman, A.M., Worcel, M., Beta 1 Adrenergic Receptor Gly389Arg Polymorphism and the Impact of Fixed Dose Combination of Isosorbide Dinitrate/Hydralazine in Heart Failure: Results from the A-HeFT Trial, *J Amer Coll Card Supplement*, 47(4), Feb 21, 2006, 67A.
 148. McNamara, D.M., Tam, S.W., Sabolinski, M.L., Tobelman, P., Palmer, A., Janosko, K., Feldman, A.M., Worcel, M., Aldosterone Synthase Promoter Polymorphism Modulates Outcome in Black Patients with Heart Failure: Results from the A-HeFT Trial, *J Amer Coll Card Supplement*, 47(4), Feb 21, 2006, 72A.
 149. Nagarakanti, R., Srinivasan, S., Kukin, M., Feldman, A.M., Whellan, D.J., It's Not Time To Needle in Acute Decompensated Heart Failure, *J. Card. Failure*, 12(6), Supp. 1, Aug 2006, S131
 150. Saxon, L., Boehmer, J., Yong, P., Galle, E., Ecklund, F., Carson, P., Feldman, A., The significance of ICD shocks in CRT treated patients in the COMPANION trial on major outcomes. *Heart Rhythm*, 2006 3(5 Supp 1): S294-5.
 150. Funakoshi, J., Herrmann, D., Good, J., Lee, L., Zhang, J., Koch, W., Feldman, A.M., Chan, T., Wild Type A₁ Adenosine Receptor and a Mutated A₁ Adenosine Receptor Differentially Induced Cardiomyopathy Gene Expression in Transgenic Mouse Hearts, *Circulation*, Supp. 114(18), Oct 31, 2006, 878.
 151. Ghali, J.K., Feldman, A.M., Saxon, L.A., DeMarco, T., Carson, P., Yong, P., Galle, E., F. Ecklund, Bristow, M.R., The Influence of Diabetes on Outcome with Cardiac Resynchronization Therapy: Results from the COMPANION Trial, *Circulation*, Supp. 114(18), Oct 31, 2006, 3581
 152. Shamimi-Noori, S., Whellan, D.J., Dasgupta, A., Adams, S., Mather, P., Rubin, S., Andrej, J., Feldman, A.M., Beta Blocker Dose Adjustment Upon Hospitalization for Acute Decompensated Heart Failure, *J Amer Coll Card, Supp.*, 49(9) March 6, 2007, 91A
 153. Anand, I.S., Carson, P., Galle, E., Song, R., Boehmer, J., Ghali, J., Jaski, B., Lindenfeld, J., O'Connor, C., Steinberg, J.S., Leigh, J., Yong, P., Kosorok, M.R., Feldman, A.M., DeMets, D., Bristow, M.R., Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients with Advanced Heart Failure, *Supp to Circulation*, 116, 16, Oct 16, 2007, 1600,
 154. Boehmer, J., DeMarco, T., Saxon, L.A., Galle, E., Schafer, J., Yong, P., Feldman, A.M., Is Early Symptomatic Improvement Associated with Long-term Benefit with Cardiac Resynchronization? Insights from the COMPANION Study, *Supp to Circulation*, 116, 16, Oct 16, 2007, 1893.
 155. Soran, O.Z., Pina, I.L., Lamas, G.A., Kelsey, S.F., Selzer, F., Pilotte, J., Feldman, A.M.,



Clinical Effects of Enhanced Heart Failure Monitoring Using a Computer Based Telephonic Monitoring System in Older Minorities and Women with Heart Failure, Submitted.

Alternative Media

1. Feldman, A.M., Is Resynchronization Therapy Cost Effective? *Audio Journal of Cardiovascular Medicine* CD (Reporting from the ACC Annual Scientific Session 2005, 11(2), Sept. 2005.

Predoctoral and Postdoctoral Trainees

<u>Predoctoral</u>	<u>Dates</u>	<u>Current Position</u>
William Veazey, M.D.	6/87 - 6/88	Resident, University of North Carolina, Chapel Hill
Rowena Tena	1/87 - 6/90	Residency, Univ of Pittsburgh Pittsburgh, PA
Donald Jackson	8/88 - 7/90	Graduate Student, Molecular Biology, Johns Hopkins Sch of Medicine, Baltimore, MD
Orm Proske, M.D.	5/90 - 9/90	Physician, Berlin, Germany
Richard Han, M.D.	7/90 - 7/91	Resident, Brigham & Women's Hospital, Boston, MA
Jennifer Lawrence, M.D.	8/92 - 7/93	Resident Johns Hopkins Hospital Baltimore, MD
Terry Edwards	7/92 - 8/93	Student, Bowman Gray Sch. of Med., Winston-Salem, NC
Albert Hwang	6/92 - 11/93	Student, U Chicago Med Sch
Ivan Colaizzi	6/95 - 8/95	Med Student, Univ of Pgh
Eric Kinder	7/95 - 7/96	Student - UCSF School of Medicine
Brett Strait	6/96 - 8/96	Student - Gettysburg College
Angela McElhaney	6/97 - 8/97	Med Student - Univ of Pgh
Aviva Zablou	6/97 - 8/97	Brown University
Kevin Callahan	6/98 - 9/98	Student - Gettysburg College



Frank Miele	6/98 - 10/98	Masters Program University of Hahneman
Kate Gold	6/99 - 8/99	Student - Duke University
Katherine Stabenow	6/00 - 7/00	Student - Miami Unv, OH
Lee Ann Hermann	6/00 - 7/00	Student - Miami Unv, OH

Thesis Committee

Lefteris C. Zacharia, PhD. ___ - 7/02 University of Pittsburgh

Post-Doctoral

Paul Kessler, M.D.	6/86 - 6/89	Assistant Professor of Medicine Johns Hopkins Univ. Sch. of Medicine, Baltimore, MD
K.B. Newman, M.D.	6/87 - 7/88	NIH - Staff Scientist
R. Blumenthal, M.D.	7/88 - 9/91	Assistant Professor of Medicine Johns Hopkins Univ. Sch. of Medicine, Baltimore, MD
W.D. Rosenblum, M.D.	7/90 - 6/94	Assistant Professor of Medicine University of Pittsburgh
K. Peter, M.D.	7/90 - 1/91	Fellow, Scripps Institute LaJolla, CA
R. Williams, M.D.	7/91 -	Assistant Professor University of Illinois
H. Seppanen, M.D.	11/92 - 7/93	University of Helsinki
C. McTiernan, Ph.D.	1/93 - 1/94	Assistant Professor, Division of Cardiology University of Pittsburgh Sch. of Med.
T. Kubota, M.D.	7/95 - 99	Assistant Professor University of Kyushu, Japan
Y.Y. Li, Ph.D.	9/95 - 99	Assistant Professor University of Pittsburgh
Ozlem Soran, M.D.	12/96 - 98	Assistant Professor of Medicine University of Ankara, Turkey
Alain Combes, M.D.**	8/96 - 99	Assistant Professor Service de Reanimation Medicale Paris, France



George Bounoutas*	8/96 - 3/99	Laboratory Technician Harvard Medical School
Daniel Wagner, M.D.**	8/96 - 3/99	Assistant Professor University of Luxembourg
Guy MacGowan, M.D.	8/96 - 7/97	Assistant Professor of Medicine University of Pittsburgh
Andrzej Janczewski, M.D.	5/98 -	Postdoctoral Fellow
Toshi Kadakomi, MD, Ph.D.	98 -	Assistant Professor of Medicine University of Pittsburgh
Ravi Ramini, M.D.	1/01 - 7/02	Cardiology Fellow University of Pittsburgh
Maliha Zahid, M.D.	3/00 – 7/02	Cardiology Fellow University of Pittsburgh
I-Wen Wang, M.D., Ph.D.	3/00 – 7/02	Cardiothoracic Surgery Fellow University of Pittsburgh
Yoshi Hiro Higuchi, MD, Ph.D.	7/01 –6/03	Postdoctoral Fellow Thomas Jefferson University
Hajime Funakoshi, MD, Ph.D.	7/03-11/06	Postdoctoral Fellow, Instructor of Medicine Thomas Jefferson University
Ellina Cheksis, MD	7/05 – pres	Postdoctoral Fellow Thomas Jefferson University
Eman Haman, MD	7/06 – pres	Postdoctoral Fellow Thomas Jefferson University
Xue Li, MD, PhD	7/05 – pres	Postdoctoral Fellow Thomas Jefferson University

*MS awarded 7/99

**Ph.D. awarded 7/99